Podcast appearances and mentions of Abbott Laboratories

Rick Sherak, CEO of Exokinetics, shares his incredible journey from serving as an Air Force officer to leading a company that develops transformative mobility devices. He discusses the importance of leadership, sales psychology, and creating compassionate company culture. Rick's passion shines through as he recounts heartwarming stories of how Exokinetics' Zeen device has profoundly improved the lives of people with mobility challenges, including children with cerebral palsy.   Guest links: https://gozeen.com/ | https://vimeo.com/1011399920 | https://vimeo.com/856975581/9994ad1cb8?share=copy Charity supported: Project ELEVATE Mobility Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host: Lindsey Dinneen Editing: Marketing Wise Producer: Velentium   EPISODE TRANSCRIPT Episode 053 - Rick Sherak [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello and welcome back to another episode of The Leading Difference podcast. I'm your host, Lindsey, and I am so excited to introduce you to my guest today, Rick Sherak. After serving as an Air Force officer, Rick spent over 25 years in the medical diagnostic industry as a commercial and product development executive. Leveraging his broad leadership and medical domain experience, he became CEO of Exokinetics in March 2024 to lead the company into its next expansion phase of market awareness and revenue growth.  Alrighty. Well, welcome, Rick, to the show. Thank you so much for joining me today. I'm so excited to speak with you. [00:01:30] Rick Sherak: Well, it's nice to meet you, Lindsey, and I'm glad to speak with you today as well. Should be fun. [00:01:36] Lindsey Dinneen: Yeah. Excellent. Well, I would love if you would start by sharing a little bit about yourself and your background and what led you to MedTech. [00:01:45] Rick Sherak: Sure. Well, so I currently live just outside of Philadelphia with my wife and our four dogs. We just recently moved here from Boston, so we've had to quickly become Philadelphia Eagles fans. Go birds. We love it here. And my background is kind of interesting, a little bit diverse. I started off my career as an Air Force officer. I tried to follow my dad in his fighter pilot footsteps. Got almost there, but I had a medical disqualification, so I had to do a land based job, but really enjoyed the Air Force. It was a great way to pay for my college and to serve my country and also to learn leadership. It was like a masterclass in leadership. Talking about getting thrown into the leadership fire, and as a young 22 year old, lead a group of people on a mission, motivate everyone, and get everyone producing at their highest capacity. So that was a great way to start. But after I got out of the Air Force, I really wanted to go back to my roots, and that's in the sciences. I've always loved the sciences, especially the biological sciences. I have a degree in biological science from Baylor University. So out of the military, I was looking for an opportunity to use my interest in something that would support my family. So I started with Abbott Laboratories. And Abbott Laboratories, back in the day, was a Fortune 100 company, one of the up and coming medtech companies, had a pharmaceutical arm, but I belonged to the medical diagnostics side of it. And it was great. They, at the time, were hiring a bunch of ex military officers to be their field sales people and none of us knew how to sell. We were all out of either the Air Force, Army, Navy or Marines, but we learned quick. We understood, you know, there's the hill we have to take, but I really respected Abbott because they trained us not only how to sell, but how to sell with integrity, right? And they also, you know, they had 200 products that we had to learn and become masters at because we were selling to hospitals and medical laboratory clinicians, etcetera. But it was a great way to start my career, and I truly found that I loved it. One, I enjoyed the sales aspect. It was fun helping people solve problems with our products, and ultimately, help the patients get the best care right from their diagnostics. But two, it also taught me that I was pretty good at it. I did very well at Abbott. I promoted several times and won some national awards. And as a result, I was recruited away by another medtech company, which was a early stage organization called Ventana Medical Systems. I intended to be there for three years and learn everything I could and then expand my career. I was there for 15 years. And we had a ball. We took this little medical diagnostic company that came up with a transformative device that would automate very complicated processes in the pathology laboratory environment. So it was disruptive technology. We were going out there with something no one had ever seen before. And I joined them pre IPO. So we went public and then we started churning and burning and impressing Wall Street every quarter so that we can up our value. 15 short years later we sold the company to Roche Diagnostics. So what a great exit and just a wonderful experience and developing my leadership cause I was management as I quickly was filling levels as we were growing. But what a wonderful ride, that's something to see, somebody with an early vision to take it step by step to a wonderful exit. But we helped a lot of people, we became a market leader in immunohistochemistry automation, and it just truly was a great experience. But after Ventana, I wanted to do something a little different. So I stepped into the world of startups. I spent about 12 years in the startup world, worked for four startups, two of which died, which happens a lot in that environment. And then the other couple did pretty well. I really enjoyed it because now I was helping people on the oncology diagnostic side of medtech. So each startup had a unique laboratory technology that would better predict the patient outcome to a particular chemotherapy or targeted immunotherapy for their cancer. So, the whole purpose was to see how can we get better predictive value so that these patients don't have to suffer unnecessarily with the wrong drug. So that, again, was just a wonderful opportunity for me because more than not, I would come into these startups and have to create the commercial organization from scratch. That means I had to hire my own national sales team, my own marketing team, my own customer service team and logistics team to handle very delicate samples. But I loved it. It, it enabled me to take everything I learned from the air force, from Abbott, from Ventana and apply it to a small company environment. And I found that it was addictive, and that's why I stayed in it for many years. But then I did another turn and I took a sidestep because I loved also, has always been kind of a frustrated engineer. I joined an engineering company that just focused on design development of medical devices, and they hired me because of my diagnostic domain experience. And I went out and found early stage companies and brought them to this engineering firm so we could take the novel technologies from these companies and make them into a product that could be commercialized. So I did that for several years. Long story short today, I'm in a completely different type of medical device environment. I'm the CEO of Exokinetics, and Exokinetics is a very unique organization in that we decided to look at the mobility device market and fill the gap, because unfortunately people with mobility challenges are basically regulated to either wheelchairs or walkers or electronic scooters, all of which have significant problems to their health because they're not using their body in many cases. And fall prevalence-- people with walkers-- oh, it's just such a shame. There's over 50, 000 emergency room visits a year of people falling with their walkers. So anyways, Exokinetics has developed a very unique mobility device that gives people a lot more freedom. and safety in their daily challenges with mobility. So, sorry, it's kind of long. [00:08:44] Lindsey Dinneen: Oh, I loved it. No, I so appreciate it. Thank you for talking us through all of that. That was great. And so many questions, but I'll try to start at the end a little bit and then probably work my way back. But yeah, so, okay. So I'd love to hear more about the company that you are now involved in and this device. But I'd love to take it back a little bit further and say, what made you aware of this challenge existing that there isn't a great solution in the marketplace, or not maybe more updated options. So what made you aware of that challenge and then decide, "Okay, I think I have the tools, resources, ideas to fix it, to address it"? [00:09:25] Rick Sherak: It's a great question. I, one, I was not aware, right? I was not aware of the challenges. However, a buddy of mine, we go to the same church, you know, we're in a men's group, we're a bunch of old guys hanging out talking about stuff. And he was doing some investment investing into early stage or startup medical diagnostic companies. A very generous individual, and he knew of my background and he goes, "Rick," he goes, "I'm looking at this company. I'm not sure I want to invest, but maybe you can look at it with me." So I did some free consulting for him, he's my friend. And then he kept dragging me to this company to their board meetings. Right. And I'm going, "Hey, this is great," and I give him my advice because, because it was new for me. And that's how I found out, Lindsey, about the challenges that people with mobility issues have, is that the status quo now is, oh, you have Parkinson's, or you have cerebral palsy, or you've had a stroke. Put those people in a wheelchair and just let them live their life at that level. And I didn't realize how horrible that is for many of these people because they still have utility of their legs, right? But when you're confined to a wheelchair for long term, your legs will naturally atrophy, right? And become so weak that they won't be able to use them anymore. So what struck me, as mission driven, was that this company invented with their own engineers, this device that not only promotes people with mobility issues to use their body, but to use their body effectively moving around horizontally around the world, but also vertically. It enables them to go from a seated position to a standing position. And for us, for you and I, we're thinking, "Well, yeah that's pretty good." For them, that is a game changer being able to go from seated position to standing and then walk from that position all without the fear of falling. So, it really touched my heart as I learned more and more about the company and I kept giving more and more time to them. So eventually I was pulled aside and they said, "Rick, what's your appetite for running this company because we need to grow it and we need to get out there and help more people." So lo and behold, I've been here for almost a year. February 1st is my anniversary and it's been a great ride. I just love it. I have a passionate team, mostly of young people. I love it. I couldn't script better people, more compassionate, more caring. All of our customers are suffering in some way or another. Even our elderly customers that are just bad knees, bad hips, bad endurance, our device is perfect for them. So, yeah, you know, we're having fun. [00:12:27] Lindsey Dinneen: That's great. Well, yeah. Thanks for sharing a little bit about that too. And so, as you've stepped into this leadership role that you weren't necessarily anticipating was your next right thing, what were some of the challenges? Because you've had an amazing career, and like you've said at the beginning, you were learning leadership skills all throughout and you've had many iterations of different ways of approaching medtech, with the industry. But now as CEO, that's another thing. And so I'm curious, how was that transition to step into this leadership role and take it on? [00:13:03] Rick Sherak: No. And it has been different in many ways, but it's also very similar in others, right? Because in my opinion, leadership, really the definition from my perspective is that a good leader motivates effectively a group of people, talented people, and usually very diverse group of people, pulls them all together to accomplish an overall mission or goal, right? And it's it. That's the part I wouldn't say that's easy about my job now as a CEO, but it's natural and I love motivating my people. I'm a big fan of management by walking around and I try to talk to all my employees at least every day or every other day just to see what's going on, not only in the business side of things, but also in their personal side of things. I, I assume that nobody's going to respect me unless I earn it. And, I just wanna make sure that I'm leading by example and I'm the guy that either gets to the office first or leaves the office last, just trying to make sure that I'm there for my people when they need me. What is different, Lindsey, is that I am struggling with delegation because I want to do it all myself, right? And I know better. It takes me a long time to dye this hair white because I'm not that old, but just know better. But it's a struggle because you have to allow others to get things done and especially in a small company like this. We were still very early stage. People are wearing a lot of hats and I just have to allow them to go and give them the best guidance I can and then press on to the next thing, right? [00:14:49] Lindsey Dinneen: Absolutely. So, it sounds like you've been very intentional building a company culture that reflects the values that you care about, of course, and also reflects compassion, because you mentioned, your customers, for instance, are all folks that are in a difficult, challenging place. So how do you feel the importance blends from really intentionally cultivating a culture that is this empathic, creative problem solving, just really good culture, it sounds like, to how that affects how you basically present to the world who you are. [00:15:28] Rick Sherak: Yeah, well, no, that's a great question. So where our challenge is that our customer base is so broad, right? And like you said, all of our customers in our DTC business-- that's about 40 percent of our business is direct to consumer, right? But we have other customers, distributors. We have hospitals that use our device, physical therapy, occupational therapy, neurological research, you know, things like that. But the key, I think, from our perspective, is we want people to realize that, hey, we don't have 20 products, right, that we've gotten from other folks. We have designed and developed a very new and transformative device that only came about because we had our own internal engineers, and we've listened to what is needed out there to help people live a better, more free, more independent and active lifestyle. So, you know, interestingly, when we broadcast ourselves out there, I hope that people realize that, "Wow, this is not just a company selling something new, they design and develop this with their own people," right? There's a lot of love in our products, and people can tell because each one of our products is handmade, and it's customized to the individual ordering it by their weight, how much they weigh, and how tall they are, so we can adjust everything for them. And I tell you it's a lot of fun because some people literally take the time when they get their Zeen-- that's the name of our product, Zeen-- but they'll write us these wonderful notes on how this device has just transformed the way that they engage with their world. And, when you sit back and you go, "Hey, what difference are we making today?" Wow. That's why I think I have such a motivated group of people because every day we're talking to these wonderful, courageous individuals that have lost a big part of their ability to live effectively in the world and they're looking for something new, something meaningful and something that's going to help them. And when we can provide that it's just wonderful, very rewarding. [00:17:52] Lindsey Dinneen: Yeah. Yeah. Of course. Just to know the impact that you're making and able to make. And so the days that get really tough or frustrating or whatever, you can still hold onto this anchor of, "But we're making a difference. We know that." [00:18:07] Rick Sherak: And we see it. We have visitors come to the factory just about every week. Maybe two or three visitors will come and they'll try it out. Try out the Zeen to say, "Hey, I saw it on social media, just want to try it. You guys are local." And that's when we really get that, that visceral customer experience, right? It's just crazy, Lindsey. I've seen people come in, bent over sitting on this little electric scooter with a joystick. And they come in and they just look broken, right? And then we get them into a Zeen, and then they're all of a sudden their spine starting to straighten, right? They start sitting up, and then we slowly and compassionately show them how the device works and everything, but we make sure that they feel safe and that they trust. And as soon as we get that go ahead, which often you just see it in their eyes, then we'll engage the levers and the Zeen will lift that person with-- it's kind of like a big bicycle seat under them. It lifts up with this non motorized lift mechanism, that we invented, up to 75 percent of a person's body weight. So now they go from the seating position to standing. Now, many of these people can't do that on their own. They can't extend their legs from seating to standing. They need other people to grab them and lift them, right? But now Zeen lifts them. Now they're standing. And again, it's just phenomenal because this person that came in on this scooter bent over is now standing. They're putting weight on their legs. They're stimulating their brain because there's weight on their legs. Right now, neural connections are starting to flow again, and their spine straightens, and they stand tall, and when they take those first steps, often it's very slow, just tiny little steps. But then we just leave them be, and we talk to their family that came with them, and we go get something to drink, get some snacks, start chatting, and just let them be. And it's amazing, you can just see their brains working, and their legs moving faster and faster. I've seen people barely moving at the beginning, and at the end, they're cruising, we call it the lap, they go around the office, around all the desks and everything, and everybody's clapping, you know. It's amazing. [00:20:28] Lindsey Dinneen: Wow. [00:20:28] Rick Sherak: It's so cool! I'm not trying to overstate it, but this is our daily life. So I'm just very happy and pleased that my background has led me here. It's a great way to finish my career. I want to stay here for as long as I can. Hopefully it'll be many years because I enjoy every day of it. [00:20:52] Lindsey Dinneen: Wow. That's incredible. Yeah, and thank you for sharing those stories. I was just imagining that, that laugh and how amazing. [00:21:00] Rick Sherak: It is so cool. [00:21:03] Lindsey Dinneen: Can't possibly get old. Just witnessing joy and hope, honestly, even hope alone is... [00:21:10] Rick Sherak: One of the best is this father comes in with his twin boys. And the boys have cerebral palsy. It's a disease that you get from birth, right? And their legs are just not good. They have no balance at all. And the father brings them in. He carries them because they don't even have a mobility device that really works for them, except for walkers, like an old person walker, right? But he carries them in, he puts them on the, in the lobby, and we bring over the Zeens, and these little boys are the cutest things you've ever seen. They're just, they're twins, they're chatty, they're so excited. We get them into the device, and their first few steps, it's like I said before, we're just tiny, tiny. But then they built their trust. And at the end of the visit, these boys were running. I mean, they were digging in with their little legs, fully supported, fully trusting the device and their hands were in the air waving. And their dad is just like tears. He's just like gushing. He's going, "One, I've never seen my sons run before. Two, they've never moved without their hands either holding a walker or crawling on the floor." He goes, "These boys are running around with their hands in there in the air." And they're saying, "Hey, look, Daddy, my hands are in the air. I don't need to use my hands." Of course, we have Kleenex boxes all over the office. [00:22:36] Lindsey Dinneen: Yeah. I'm pretty sure you'd have to, it's just part of the the office supplies. [00:22:42] Rick Sherak: Exactly. Yeah. We have a Costco membership for regular shipment of Kleenex. Yeah. [00:22:49] Lindsey Dinneen: That's amazing. Oh, thank you so much for sharing that story. That's incredible... [00:22:53] Rick Sherak: Oh, yeah. [00:22:54] Lindsey Dinneen: ...just for a father's heart. [00:22:56] Rick Sherak: Oh, it's just so amazing. Yeah, it's so amazing. [00:23:00] Lindsey Dinneen: So this is all incredibly exciting just the way it is right now, but I imagine there are future plans. Can you share a little bit about what's next? What are you excited about as you move forward? [00:23:12] Rick Sherak: Well, what's really exciting is our growth potential, right? So again, the Zeen is a very unique device, but it fits so many different segments of populations. Like we've been talking about people with chronic illness. That is our core group, right? We work with people with Parkinson's, MS, muscular dystrophy, cerebral palsy, ataxia, you know, just about anything like that where people have strength, balance, or endurance issues. The other part that we're really excited about this year is that we didn't realize until those boys, how much our Zeen would help in the pediatric environment. So now we're making a very concerted effort going after the children's hospital physical therapy groups, showing them the amazing utility of a Zeen. And also because it's so adjustable, a person, a child can get into a Zeen early, let's say at the age of seven, and it could actually stay and grow with them until they're 14 or 15 years old. The whole thing adjusts up. So we're very excited about that market space. And we're also introducing the Zeen to luxury senior centers, because so many of our Zeen customers are just elderly people that don't want to give up, that have this incredible determination to either maintain or regain their mobility. Their knees hurt, their hips hurt, their endurance is down. So that's another avenue that we're introducing ourselves to, primarily through social media and publications through PR. But we're hoping this new awareness will get more Zeens out there. Our goal is really awareness. And that's one of the reasons that you and I are talking. I want to get out there as much as possible and let people know that there's other alternatives out there for their loved ones or for themselves if they have mobility challenges. And please check us out. We have a really cool website, a lot of videos, a lot of testimonials, and we just love helping people. And we're very fair in business. Our product is not cheap, but we give most customers a 14 day minimum home trial, and we say, "Use it a lot, as much as you can to make sure it's a good fit." If you don't like it, money back. So we try to be as fair as possible to make sure it's a good fit. [00:25:39] Lindsey Dinneen: Yeah, that sounds good. Yeah. And so for any of our listeners that are, you know, going to go and check out the website, just make sure you have your own stash of Kleenex. Oh man. [00:25:54] Rick Sherak: And every time we sell a Zeen, it comes with a virtual training session. So it's a one on one with one of my specialists. And I tell you, these folks are the best. So the best trainers and they're just the most delightful people, right? And they're like you. They're virtual, but you feel like they're right there with you. So we do virtual training for every one of our customers. And, it gives us that opportunity to see people eye to eye and to ensure that they understand their new tool and how to use it and how to, like I mentioned before, how to trust it, and realize that they're not going to fall, that they can move again, and they can do it safely. [00:26:34] Lindsey Dinneen: Amazing. Well, gosh, thank you so much for sharing about the company and... [00:26:38] Rick Sherak: Yeah. [00:26:39] Lindsey Dinneen: ...the device and the lives that it's impacting. And I just, I love learning about this. I'm so excited about the work that you're doing. So thank you for putting in the work. It's not easy. Startup world is difficult and especially medtech, but you've done it. So good job. [00:26:56] Rick Sherak: Well, and this is also interesting for me because it's manufacturing. Before, I didn't have to manage manufacturing. So manufacturing is a whole different beast with getting your parts, getting them ordered in time 'cause everything has to be built just right. This is like a high end super bike, you know, has the latest in technology for aluminum framing and engineering leverage. So that's a challenge for sure. But the other thing I wanted to plug real quick, Lindsey, if you don't mind, is again, we're a premium priced product, but we're not covered under insurance plans right now. That means Medicare or Medicaid. So, part of our outreach is we've created a foundation. It's a nonprofit foundation so that if we can find donors that want to support, the money goes into our foundation, and we take applicants and we provide grants for up to half the cost of a Zeen through the foundation. The other half is on the people that are trying to buy it. And, it's so interesting. Talking about putting skin in the game, right? People call and say, "Geez, I just can't swing that amount of money." Well, let's talk about the foundation, but you have to come up with half. And that creates such a-- it's such a partnership, and they're so excited. They'll be emailing my folks going, "Hey, I was able to raise 500 through a crowdfund! I just got to keep going!" And we're going, "Yeah, keep going!" And as soon as we hit that halfway mark, the foundation kicks in and covers it. So again, I just want to put a plug out there so that we can help very deserving people that just financially need a little support. Yeah. [00:28:37] Lindsey Dinneen: I love that. So that's a great way for even listeners to get involved, even if they don't necessarily personally need the device, but donating to this incredible cause, that would be awesome too. [00:28:48] Rick Sherak: Anything would be so appreciated. [00:28:50] Lindsey Dinneen: Great. Yes, absolutely. Well, okay. So pivoting the conversation a little bit just for fun. Imagine that you were to be offered a million dollars to teach a master class on anything you want. It can be within your industry currently, it could be about anything. What would you choose to teach? [00:29:13] Rick Sherak: You know, that's funny that you said that. I live right next to Villanova University, and a lot of my neighbors are professors there. And one of our best friends that lives a few houses down she's in the business ethics department. And she even said, she goes, "Rick, have you ever thought about teaching?" And I said, "You know, I've never really been a teacher." But if I were to teach, the thing I would love to do would be to capture over all these years of me being in this industry, the nuances of the psychology of sales. Because people think of sales as, "Oh, you're trying to trick people into buying, right?" Turn that completely upside down to, you're trying to assist people to buy. Because people really, when they're looking at your product, they want it. But they need help. They're counting on you to help them in that process. And it's a psychological bond when you're talking to somebody and you have a product and they have a need and you're trying to find that, that perfect combination, right? So that they feel, "Hey, this is great for me. It's worth every penny because I see the value." Versus having them feel, "Oh man, I'm going to get ripped off." So I would love to go down that path. I think that's so interesting because people are people, and salespeople, the best ones I've ever seen, like I mentioned before, are compassionate and caring, but they're also pleasantly persistent, right? And they just, they go, they listen and they say, "All right, but let's keep moving down the path." And people that are on the buying side truly want that. They want that partnership, that walking side by side down that path to purchase, because sometimes they're not courageous enough to buy just by themselves. So, to destigmatize sales would be kind of fun. [00:31:13] Lindsey Dinneen: I love that. That would be great. That'd be a great masterclass too, just to really dive into some of that, and yeah, to put a different perspective on your role and you're helping somebody to achieve what their goals are, to be honest. [00:31:26] Rick Sherak: Absolutely. [00:31:27] Lindsey Dinneen: I love that. [00:31:28] Rick Sherak: Absolutely. And we've all had those good experiences, and we've all had those bad experiences. [00:31:32] Lindsey Dinneen: Definitely. Definitely. So how do you wish to be remembered after you leave this world? [00:31:40] Rick Sherak: You know, that, that's interesting because I love to read. My morning time is my reading time. That's my time. It's me and my two collies. They're also early risers. The pugs, the two pugs, no, they'll sleep in with their mother. But in my reading and in my studies, essentially, I think it all boils down to at the end of the day, when the curtain starts coming down, wouldn't it be nice, when you're out, you're no longer here and people look back and they just say, "You know what? That guy or that lady really genuinely cared about other people." I think authenticity and being genuine is something I would love to be remembered for. And it's not easy, because sometimes you're not authentic to yourself, yet to others. [00:32:29] Lindsey Dinneen: Yeah. [00:32:32] Rick Sherak: But especially at this stage in my life, I just see caring for people is just amazing. Talking about, if everybody cared a little bit more for each other, it might be a different place. [00:32:43] Lindsey Dinneen: Yeah. And having the courage to be authentic and honest can sometimes also be, it does come with a little bit of vulnerability. So I love that. [00:32:55] Rick Sherak: Oh yeah. Oh my gosh. You know, it's all about, if you're just so lucky to have a little bit of grace, a little bit of wisdom, but like you said, a lot of courage. That's when it all means something, right? Cool. Oh. [00:33:10] Lindsey Dinneen: I know. What is one thing that makes you smile every time you see or think about it? [00:33:22] Rick Sherak: Well, you know, funny because we've been talking about leadership and sales. I just got to tell you a quick story because it always makes me smile. As I mentioned before, I was an Air Force officer and all of a sudden I jump out of the Air Force into a sales role with a medical diagnostic company. And, I just went through training. I got assigned to my territory. Baton Rouge, Louisiana. I'm a Colorado boy. So Baton Rouge, Louisiana was a little bit different for me, but the company moved me down there, and I started my sales career. And my, my customers were all hospitals and clinical laboratories in Baton Rouge, Lafayette, and the Bayou South, all those little towns in there. And I didn't realize it until after I started, but my territory was made out of the accounts the other sales people didn't want. [00:34:16] Lindsey Dinneen: Oh. [00:34:17] Rick Sherak: So the guys that were there, they cherry pick the good accounts, and the ones they didn't want, they made into my territory, right? The new guy. But I went in, I was dialed in. I had my brochures. I knew all my product knowledge. And I'd make appointments and I'd sit in front of these lab managers and these clinical influencers. And these lovely people, they would sit there. They would be so kind. They'd have their arms crossed. I go through my spiel and then they just look at me and they say, "Thank you, Rick, for coming. I'm not interested at this time." I go, "Okay." So this went on, Lindsey, for six months at every single hospital or clinical laboratory. I was like on the bottom of the sales list. I couldn't get anybody to buy anything. And it was like, it was so funny. And this is what makes me laugh. I'll never forget. I was down in south of Lafayette, and I was sitting in front of this lab manager and I've seen him every three weeks like clock work, right? And I'd always bring in new information, recap what we discussed before, and asked for the business. And he'd always say, "No, I'm not interested." But about six months in, he just looked at me and I got through my spiel. And he goes, "Rick," he goes, "Are you just going to keep showing up every three weeks?" And I said, "Yes, sir." And he says, "Look," and I mean, he's going, "Well, I'm not buying anything from you." And I said, "Yes, sir. But I, I truly feel that my products are the best products that you could use in your laboratory to make you more successful and to give your patients the best diagnostic information to help them fight their disease." Because it was mostly oncology focused. And he just looked at me and he goes, "You truly believe that?" I said, "Yes sir, I truly believe and I'm going to keep coming back until you believe." And he just sits back and he, I'll never forget this, he unfolded his arms, put his hands on the table and he goes, "Well, okay, then let me see what you got." And it was awesome. Lindsey, I swear there was like some underground communication channel because every hospital or clinical laboratory started listening to me after about six months. It was weird. And then another six months, I was on top of the sales rolls, and I had turned my territory around and we were just having a ball. But it was that persistence, it was just in the caring. I just cared. I was convinced my products were better, and he appreciated that. And, it, it was a fun, it makes me smile today because there's nothing like seeing somebody say, "Well, you know what, I trust you enough to listen to you now." [00:37:06] Lindsey Dinneen: Yeah. Wow, that's awesome. They really had to go through that know, like, and trust you cycle or a journey. [00:37:15] Rick Sherak: These are long term Louisianians. I'm coming in as an outsider, too. So that was, I had to prove myself. But they are the one most wonderful people. Before I got promoted out of that territory, I used to show up at least once every, maybe two months, per hospital with all these crawfish and a big old pot and a boiler and I would be out in the parking lot. I'd be boiling crawfish and I called the lab and I'd say, "Hey guys, I got crawfish!" And they go, "Oh, Rick has crawfish!" And they all come out and we'd all eat crawfish. That's how you do it in Louisiana. It was a good time. [00:37:54] Lindsey Dinneen: Very cool. Thank you. Thank you so much for sharing about that. And just in general, being so willing to share so much of your story. I really appreciate it. I loved getting an opportunity to learn about you and your background and your heart for MedTech, your heart for the people that you're serving. So thank you. I know days aren't always a walk in the park as much fun as I know you're having, but I know you have good days and bad days. So thank you again so much for joining me. [00:38:19] Rick Sherak: Thank you, Lindsey. [00:38:20] Lindsey Dinneen: And I just wish you the most continued success as you continue to work to change lives for a better world. And just also thanks to our listeners for tuning in. And if you're feeling as inspired as I am, I'd love it if you'd share this episode with a colleague or two and we'll catch you next time. [00:38:40] Ben Trombold: The Leading Difference is brought to you by Velentium. Velentium is a full-service CDMO with 100% in-house capability to design, develop, and manufacture medical devices from class two wearables to class three active implantable medical devices. Velentium specializes in active implantables, leads, programmers, and accessories across a wide range of indications, such as neuromodulation, deep brain stimulation, cardiac management, and diabetes management. Velentium's core competencies include electrical, firmware, and mechanical design, mobile apps, embedded cybersecurity, human factors and usability, automated test systems, systems engineering, and contract manufacturing. Velentium works with clients worldwide, from startups seeking funding to established Fortune 100 companies. Visit velentium.com to explore your next step in medical device development.

Steve Grzanich has the business news of the day with the Wintrust Business Minute. Suburban-based Abbott Laboratories says it will spend $500 million on two manufacturing facilities, including one in Illinois. The investments come despite new and threatened tariffs, including some on medical devices and diagnostics. Abbott says the investments will help the company boost […]

Vistazo a Nvidia tras anunciar que asumirá un cargo de 5.500 millones por las restricciones a China. Miramos también a Travelers y Abbott Laboratories, que han presentado cuentas. Con Candela Casanueva, gestora de Renta 4 Gestora.

Vistazo a Nvidia tras anunciar que asumirá un cargo de 5.500 millones por las restricciones a China. Miramos también a Travelers y Abbott Laboratories, que han presentado cuentas. Con Candela Casanueva, gestora de Renta 4 Gestora.

Vistazo a Nvidia tras anunciar que asumirá un cargo de 5.500 millones por las restricciones a China. Miramos también a Travelers y Abbott Laboratories, que han presentado cuentas. Con Candela Casanueva, gestora de Renta 4 Gestora.

From navigating the halls of Abbott Laboratories and Knoll Pharmaceutical Company to pioneering his path as an independent medical device sales rep, Bruce Brown's career journey challenges traditional sales wisdom. In this episode, he reveals the innovative strategies that helped him thrive in both worlds - including an ingenious FedEx tactic that changed his pharmaceutical sales game. Bruce opens up about the real rewards and challenges of transitioning to 1099 medical device sales, offering a no-nonsense look at building surgeon relationships and handling industry hurdles. His candid insights cover everything from managing non-payment issues to adapting to generational shifts among doctors, providing listeners with actionable strategies for success in the medical sales field. Whether you're a pharmaceutical rep considering medical devices or a sales professional looking to go independent, Bruce's two decades of experience offer a practical blueprint for making the leap. He shares specific resources, proven approaches for product innovation, and the mindset shifts needed to thrive in today's evolving healthcare landscape. Connect with him: LinkedIn Best Book: Founding Fathers: The Essential Guide to the Men Who Made America. Remember to subscribe to our Podcast for more valuable episodes.

After a short hiatus, the Great Trials team is back in action! This week, Steve and Yvonne interview Jake Plattenberger and Alan Holcomb of TorHoerman Law about the high-stakes legal battle, Margo Gill vs. Abbott Laboratories. The case revolves around a $495 million verdict awarded to Margo Gill, representing her daughter Robynn Davis, who suffered catastrophic injuries from necrotizing enterocolitis (NEC) after being fed Similac Special Care 24 formula by Abbott Labs.    Remember to rate and review GTP in iTunes: Click Here to Rate and Review   Case Details: Margo Gill's premature infant daughter, Robynn Davis, was born on August 26, 2021, at SSM St. Mary's Hospital in St. Louis, Missouri. Shortly after birth, doctors transferred Robynn to Cardinal Glennon Children's Hospital, where she was fed Similac cow's milk-based formula, manufactured by Abbott Laboratories. After consuming these products, Robynn developed necrotizing enterocolitis (NEC), a life-threatening gastrointestinal disease that primarily affects premature infants. As a result of NEC, Robynn required extensive surgery and now faces long-term health complications. The complaint alleged that Abbott Laboratories, along with sales representatives Matthew McClure and Tara Todd, aggressively marketed their cow's milk-based formula as safe for premature infants, despite being aware that it significantly increased the risk of NEC. It also claims Abbott failed to provide adequate warnings about the risks of NEC. Additionally, Abbott falsely promoted their formula as essential for the growth and development of preterm infants. (Source)   Guest Bios: Jake Plattenberger Since joining TorHoerman Law in 2009, Jacob Plattenberger has taken hundreds of depositions, argued in countless hearings, and tried over thirty-five (35) cases to a jury. His experience in and out of the courtroom has made him a passionate advocate for those injured due to the negligence of others. Jake started his career trying cases at one of the busiest civil courthouses in the country – the Richard J. Daley Center in downtown Chicago. He started out doing insurance defense because he knew that afforded him the best opportunity to get courtroom experience. “When I was working on the defense side, I always knew that I was going to be a plaintiff's lawyer. I knew that being able and willing to try a case to a jury was a skill that I needed to have if I was going to be able to offer my clients the best legal representation. Insurance companies and corporate defendants need to believe you when you say you will take them to trial – they need to fear that.” This type of real trial experience is exceedingly rare in complex civil litigation and having seen it from the defense side gives Jake an added advantage. Read Full Bio   Alan Holcomb Alan Holcomb brings over a decade of experience handling catastrophic injury cases to the team. Widely recognized for his legal advocacy and broad experience as a trial lawyer, Alan has handled cases in more than 20 states nationwide.  Alan works on cases ranging from products liability, severe burn injuries, wrongful death, chemical exposure, car accidents, lung disease, negligent security, and more. He puts his diverse expertise to work for his clients every day, dedicating his life to representing the people. After earning his undergraduate degree from the University of Georgia, Alan received his juris doctorate from Emory University School of Law. Before forming Turnbull, Holcomb & Moak, Alan was an equity partner at one of the top insurance defense firms in the country, where he represented some of the largest companies in the world and acted as national coordinating counsel for a large chemical/flavor manufacturer. This experience taught Alan that he wanted to help equalize the power imbalance between well-funded corporations and consumers, leading him to a career fighting for the people as a plaintiff's attorney. Licensed in Georgia, California, Mississippi, and Ohio, Alan is determined to hold major corporations accountable. He relentlessly pursues justice, passionately advocating for his clients every step of the way. Read Full Bio   Links: TorHoerman Law on Facebook: THLawyers Check out previous episodes and meet the GTP Team: Great Trials Podcast   Show Sponsors: Harris Lowry Manton LLP - hlmlawfirm.com   Free Resources: Stages Of A Jury Trial - Part 1 Stages Of A Jury Trial - Part 2

The Daily Business and Finance Show - Saturday, 14 December 2024 We get our business and finance news from Seeking Alpha and you should too! Subscribe to Seeking Alpha Premium for more in-depth market news and help support this podcast. Free for 14-days! Please click here for more info: Subscribe to Seeking Alpha Premium News Today's headlines: Walgreens gains on report of bidder lining up debt financing for takeover Elon Musk discloses SEC settlement demand, Neuralink investigation CVS, Cigna could be hit hard by PBM reform: Deutsche Bank Tesla stock rises on report of Trump team looking to scrap autonomous crash reporting SCOTUS agrees to hear case on California's unique emission standards Editas to cut 65% of workforce in strategy shift; shelves lead gene-editing program Old Republic declares $2.00 special dividend Abbott Laboratories raises dividend by 7.3% to $0.59 Bill Ackman says he's short IEP, long FNMA for stock-picking contest Explanations from OpenAI ChatGPT API with proprietary prompts. This podcast provides information only and should not be construed as financial or business advice. This podcast is produced by Klassic Studios Learn more about your ad choices. Visit megaphone.fm/adchoices

Causation in Law Source: Podcast: Causation: The Link Between Conduct and Harm Main Themes: Defining and differentiating factual and proximate causation. Applying causation principles in tort and criminal law. Examining challenges in proving causation, especially in complex cases. Highlighting landmark cases and their impact on legal precedent. Understanding the interplay between causation and public policy considerations. Most Important Ideas and Facts: 1. Two Components of Causation: Factual Causation ("But-For" Test): Establishes whether the harm would have occurred "but for" the defendant's actions. Example: "If a person sets a fire in a building, causing another person to die in the flames, factual causation is established if the victim's death would not have occurred 'but for' the fire set by the defendant." Proximate Causation (Legal Causation): Evaluates whether the harm was a foreseeable consequence of the defendant's actions, even if factual causation is established. Example: The landmark case Palsgraf v. Long Island Railroad Co. illustrates the limits of proximate causation by finding no liability when a series of unforeseeable events led to injury. 2. Causation in Tort Law: Negligence Claims: Causation is essential to prove duty, breach, causation, and damages. Concurrent Causation: Multiple parties can share liability for contributing to the harm. Example: Two factories polluting the same river can be held jointly liable for environmental damage. Intervening and Superseding Causes: These events can modify or relieve liability based on foreseeability. 3. Causation in Criminal Law: Focus on Culpability and Punishment: Requires proving both factual and proximate causation to establish criminal liability. Intervening Acts: Their impact on liability depends on their foreseeability in relation to the defendant's actions. 4. Special Considerations and Challenges: Multiple Causes: Determining each party's contribution to the harm is crucial, as seen in joint and several liability cases. Scientific Uncertainty: Difficulties arise in proving causation in environmental and toxic tort cases with complex scientific evidence. Market Share Liability: Provides a solution when identifying the specific defendant is impossible, as demonstrated in Sindell v. Abbott Laboratories. 5. Landmark Cases: Barnett v. Chelsea & Kensington Hospital: Highlights the importance of factual causation in establishing liability. Wagon Mound (No. 1): Emphasizes foreseeability as a key factor in proximate causation. Derdiarian v. Felix Contracting Corp.: Demonstrates the role of foreseeability in evaluating intervening causes. 6. Public Policy Considerations: Causation doctrines are not just technical rules but reflect broader societal values and aims, like deterring harmful practices and protecting vulnerable individuals. Courts balance the interests of plaintiffs and defendants to ensure fair outcomes and proportionate liability. Key Quotes: "Causation is what connects the defendant's actions or omissions to the harm suffered by the plaintiff or victim. Without causation, there can be no liability, no damages, and ultimately, no justice." "Imagine a world without causation standards—people could be held liable for harms with only a tenuous connection to their actions, leading to unpredictability and injustice." "Causation is a fundamental concept in tort and criminal law, providing the essential link between conduct and liability." Conclusion: Understanding causation is crucial for legal professionals, as it lies at the heart of determining liability and achieving just outcomes in various legal contexts. The principles and doctrines discussed in the podcast, combined with the landmark case examples, provide a comprehensive overview of this vital legal concept. By understanding the nuances of causation, one can better analyze legal situations and advocate for fair and equitable resolutions. --- Support this podcast: https://podcasters.spotify.com/pod/show/law-school/support

In this episode of the Supply Chain Careers Podcast, we speak with Mike Leggett, Chief Supply Chain Officer for La-Z-Boy, who has also progressed through positions at Kimberly Clark, Abbott Laboratories, Masonite, and Dentsply Sirona. Mike got his start in supply chain pursuing finance at Ohio State, but after attending a Transportation Logistics Association meeting and enjoying the free pizza, found that a speaker from Big Lots inspired him to look further into supply chain. He shares his transitions and growth path on the way up to CSCO, knowing he wanted to be a leader. Mike provides his thoughts about how to establish breadth of experiences, including vital operations experience, that helps him lead a broad team of VPs. He shares his mentors' advice and the value of being a servant leader. He also seeks continuous feedback and asks as many questions as he can about how he is doing and the directions he should be taking. Mike highly values curiosity, intelligence, and analytic capabilities, but values attitude most of all. In this episode Mike also addresses international experiences, networking, establishing relationships, setting proper expectations, and asking what more you can do.Need help hiring top talent? Engage a recruiting firm that specializes in your hiring needs: Supply Chain Recruiters Operations Recruiters Manufacturing Recruiters Distribution Center & Warehouse Recruiters Continuous Improvement Recruiters S&OP Recruiters Strategic Sourcing & Procurement Recruiters Inventory Planning Recruiters Transportation & Logistics Recruiters

Celso Otero, gestor de fondos de Renta 4 Gestora, analiza este miércoles en Capital Radio los valores de Morgan Stanley, US Bancorp, JP Morgan, Abbott Laboratories, Kinder Morgan y United Airlines, entre otras compañías.

Steve Grzanich has the business news of the day with the Wintrust Business Minute. Abbott Laboratories is launching a $7 billion stock buyback program. The North Chicago-based company made the announcement as it reported 3rd quarter earnings. The stock buyback was approved earlier this month by Abbott’s board of directors. The company says sales rose […]

Nos fijamos hoy en Morgan Stanley, US Bancorp, JP Morgan, Abbott Laboratories, Kinder Morgan o United Airlines con Celso Otero, gestor de fondos de Renta 4 Gestora.

Join Ben and Rahul for their discussion with Jake and Tor, breaking down the recent 495 million Dollar verdict in a product liability case against Abbott Laboratories for pre-term infant formula that increases the risks for developing necrotizing enterocolitis. Hear how Jake and Tor navigated this difficult case and won this epic battle. About Jacob Plattenbergerhttps://www.torhoermanlaw.com/team/jake-plattenberger/Jacob Plattenberger has taken hundreds of depositions, argued in countless hearings, and tried over 35 cases to a jury.His experience in and out of the courtroom has made him a passionate advocate for those injured due to the negligence of others.Jake started his career trying cases at one of the busiest civil courthouses in the country – the Richard J. Daley Center in downtown Chicago.He started out doing insurance defense because he knew that afforded him the best opportunity to get courtroom experience.“When I was working on the defense side, I always knew that I was going to be a plaintiff's lawyer. I knew that being able and willing to try a case to a jury was a skill that I needed to have if I was going to be able to offer my clients the best legal representation. Insurance companies and corporate defendants need to believe you when you say you will take them to trial – they need to fear that.”This type of real trial experience is exceedingly rare in complex civil litigation and having seen it from the defense side gives Jake an added advantage.At TorHoerman Law, Jake manages our Chicago office where he leads trial teams in nationwide, complex litigations such as:Representing dozens of workers across the United States who were exposed to Diacetyl at work and now suffer lung diseaseeg. The Juul/E-cigarette LitigationThe Incretin Mimetics Products Liability Litigation, currently pending in the Southern District of California, where he was named to the Plaintiff's Steering CommitteeVarious Transvaginal Mesh multidistrict litigations that are currently pendingJake also maintains a personal injury practice in Chicago, representing people and their families who have been victims of catastrophic auto and truck accidents, products liability, maritime accidents, premises liability, and medical negligence.Jake believes that to successfully represent his clients, it is absolutely necessary to get personally involved.Jake's quote below perfectly reflects that belief! Notable Cases & ResultsIncretin Mimetics – Products Liability Litigation, MDL Case No. 13MD2452 AJB (MDD). Appointed to the Plaintiff's Steering Committee by Judge Battaglia in the MDL. The case is pending.JUUL E-Cigarettes – Products Liability Litigation, JCCP No. 5052. Appointed to the Plaintiff's Steering Committee by Judge Anne Jones in the JCCP. The case is pending.Diacetyl – Leads the Diacetyl litigation for TorHoerman Law. Previous settlements and verdicts have exceeded $5,000,000.00 to date. Litigation is currently ongoing.Actos Related Cases, MDL Case No. 11 L 10011, Et. Al. – Actively participated in managing the case for TorHoerman Law which resulted in a $2.4 billion settlement.Gadolinium-based Contrast Agents Litigation Case No. 279 and Products Liability Litigation MDL No. 1909 – Managed the cases for TorHoerman Law which resulted in a large, confidential settlement.Bus Accident – Handled a bus accident injury case in which an individual was thrown from a seat. Resulted in a $850,000.00 settlement.Auto Accident – Handled an auto accident injury case that resulted in a $650,000.00 settlement.Slip and Fall – Handled a slip and fall accident that occurred on a sightseeing boat in Chicago. Resulted in a $490,000.00 settlement. Personal LifeJake was born and raised in Chicago.He now lives in the Chicago suburbs, where his two young sons keep him busy.When he isn't working, Jake is a lifelong Bears and Cubs fan and loves participating in the (mostly) healthy rivalry between the Cubs and Cardinals fans at TorHoerman Law.   About Tor Hoermanhttps://www.torhoermanlaw.com/team/tor-hoerman/Tor Hoerman is a nationally recognized attorney who has served in the field for more than 25 years.He is most well-known as the founder of the personal injury law firm TorHoerman Law, LLC (THL). Early Life & EducationTor was born the youngest of four boys on July 16, 1969, in Bethesda, Maryland to Kirk and Greta Hoerman.With his father serving as a Captain in the Navy, Tor often moved towns during his childhood, eventually landing in the Chicago metropolitan area.In Chicago, Tor lived in the Great Lakes Naval Base and Lake Bluff before his family settled in Lake Forest, which is where he attended high school.Despite repeatedly switching homes, Tor made the most of his situation.In high school, he played football, basketball, and baseball, and he earned varsity letters in each of these sports.In addition to varsity recognition, he was recognized as an All-county athlete and awarded the Booster Club Athlete of the Year his senior year.Outside of sports, Tor coached little league baseball, served as a summer camp counselor, and worked as a summertime janitor at his former high school after graduating.Tor attended Depauw University and majored in Political Science.He played NCAA baseball and football at Depauw, and he was the captain of the baseball team.After graduating from Depauw in 1991, Tor enrolled in the Chicago-Kent College of Law.During law school, Tor bartended at a local bar and clerked for Kravolec, Jambois & Schwartz, LLC. Legal CareerAfter graduating from law school in 1995, Tor took on a job doing insurance defense at Bolero, Cart & Stone, LLC, where he worked reluctantly for a year and a half.One day at work, Tor received a phone call from Steve Jambois, his former employer throughout law school, asking if he wanted a job on the plaintiff's side of insurance law.Tor immediately accepted the job, kickstarting decades to come of fighting corporations on behalf of harmed individuals.Tor's Transition to Medical Malpractice LitigationTor returned to Kravolec, Jambois & Schwartz to fight on behalf of medical malpractice victims, which mostly consisted of high-intensity trial work in the Chicago courthouse.After seven years at the Jambois firm, Hoeman was recruited by the Simmons law firm, based in an Illinois suburb of St. Louis, to start and lead a branch of the practice that focused on pharmaceutical litigation.Leading the Pharmaceutical Practice at Simmons Law FirmTor became a partner of what is now Simmons, Hanly, and Conroy and led the pharmaceutical practice for seven years.One of Tor most notable achievements while leading the practice was his work against Purdue Pharma and its reckless distribution of OxyContin.Tor was the first to file a case alleging Purdue Pharma's wrongdoing in distributing OxyContin and failing to adequately warn healthcare providers and the public of the risks of addiction.Achieving Justice Against Purdue PharmaHe led the litigation process and got Purdue Pharma to agree to a large settlement, which was distributed to thousands of accidental addicts.Tor took a step further to achieve justice in this case, assisting the Department of Justice in obtaining guilty pleas by Purdue Pharma representatives who had a direct role in contributing to the opioid epidemic. Founding TorHoerman LawHaving garnered success leading the pharmaceutical branch at the Simmons firm, Tor amicably decided to split from Simmons in 2009 and start his own pharmaceutical and personal injury practice called TorHoerman Law, LLC (THL).After negotiating the terms of the split, Tor struck a deal that allowed him to bring his entire staff from Simmons to his new practice, which summed up to more than 25 lawyers and staff members.Expansion and Success of THLTor opened offices in Edwardsville, IL; Clayton, MO; and Chicago, IL to kickstart operations; all three offices remain open today.In the time since opening THL, Tor and his team have litigated many pharmaceutical malpractice and personal injury cases.Notable Successes at THLTor's most notable successes while operating THL are perhaps co-leading the litigations against Boehringer Ingelheim's Pradaxa and Takeda's Actos.Through intense research and vetting, Tor was able to find substantial evidence indicating Actos causes bladder cancer and Pradaxa causes internal bleeding.He then presented the evidence to the companies, which decided to settle the cases.Tor played a significant role in negotiating these settlements, which ended up being $650 million for Pradaxa and $2.4 billion for Actos.Tor has also had major success in several other product liability lawsuits, such as Zelnorm, Gadolinium-based Contrast Agents, and Incretin Mimetics.We've outlined these cases, a few other notable cases, and their correlating results in the section below.Recognition & AwardsHis successes with these cases and beyond earned him the distinction as a Top 25 Notable Alumni from the Chicago-Kent School of Law, which was awarded to him and 24 other lawyers out of the tens of thousands who have graduated from the school since its founding in 1888.Tor is also recognized as a Top 100 National Trial Lawyer by the National Trial Lawyers Organization. Notable Cases & ResultsPradaxa (Dabigatran Etexilate) – Products Liability Litigation, MDL 2385 – Appointed by Judge Herndon as national lead counsel in the MDL. After protracted litigation successfully negotiated a $650 million settlement.Actos Related Cases, MDL Case No. 11 L 10011, Et. Al. – Appointed by Judge Dooling as lead counsel in Cook County consolidated docket (over 4400 cases). After protracted litigation, he was one of four lead negotiators (along with Pete Flowers, Mark Lanier, and Andy Birchfield) on a $2.4 billion settlement.Incretin Mimetics Products Liability Litigation, MDL Case No. 13MD2452 AJB (MDD) – Appointed as lead counsel by Judge Battaglia in the MDL. The case is pending.OxyContin – Represented thousands of “accidental addicts”. After protracted litigation, he negotiated a large settlement and assisted the DOJ in obtaining guilty pleas by corporate representatives.Zelnorm Litigation., Case No. 280 – Appointed lead counsel in NJ state court consolidation, took the major depositions and negotiated a confidential settlement.Gadolinium-based Contrast Agents Litigation Case No. 279 and Products Liability Litigation MDL No. 1909 – Appointed by Judge Polster as both the state and federal liaison and lead counsel in the Cook County consolidated docket. He negotiated large, confidential, individual settlements. Involvement in the Legal CommunityIn addition to his litigation work, Tor is on the Board of Managers of the Illinois Trial Lawyer Association and an Executive Board Member of the Mass Torts Trial Lawyer Association.He also attends national legal conferences on a yearly basis. Personal LifePersonally, Tor is the proud father of Casey, Kirsten and Quinn, and husband of Jessica.He tries to stay active, including still playing baseball.

In this podcast you'll meet my brother Noah Teicher, and my nephew Colton Teicher. I have two younger brothers, but my brother Noah (the middle child) has two boys who had a rare disease. And we talk about their journey from having a rare disease to being cured. Noah and Colton talk about their journey with the Children's Organ Transplant Association (COTA). Rick Lofgren has been the non profits president for more than two decades. Rick helps raise millions each year to support families with the cost for transplantation. In addition to all he does, Rick is married with kids of his own.I learned about Rick, from my brother.  My nephews Colton and Caden had a rare disease called Chronic Granulomatous Disease (CGD). CGD is passed down through the mother, only to sons, not daughters. CGD causes frequent and life-threatening infections because their immune system can't fight off certain harmful bacteria and fungi. My nephew's mother is the carrier. Women do are only carriers of the genetic disease, only boys have the genetic diesase. The great news: there is a cure. Both my nephews were cured. About my brother and nephew. Noah works for Abbott Laboratories as a district manager across several states and has three kids, and a stepson wife his wife Lisa. My nephew Colton is a Patient Care Coordinator at a specialty Pharmacy in Detroit. Colton is an advocate for his disease and the rare community.This is a reminder that it's good to share information because after my brother told me about COTA, I connected with Rick at COTA.  The Bonnell Foundation and COTA are now partners helping people who need funds for transplants, and all that it entails.Colton will be post transplant for three years on September 3rd, 2021Caden will be post transplant on December 16th, 2022To connect with Colton: coltonteicher@yahoo.comTo connect with Noah: noahteicher@yahoo.comFor information about COTA:  https://cota.org/get-started/   Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Thanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

Plus: McDonald's shares rise despite the company reporting lower quarterly sales. Shares of Abbott Laboratories decline after a jury finds the company failed to warn that its Similac formula for premature infants caused a bowel disease. J.R. Whalen reports. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Steve Grzanich has the business news of the day with the Wintrust Business Minute. Suburban-based Abbott Laboratories has been ordered to pay nearly $500 million in a case involving its baby formula. The jury award came in a lawsuit that alleged Abbott’s premature infant formula causes a potentially fatal bowel disease. A jury made the […]

Philips ziet een heuse ommezwaai: voor het eerst in twee jaar tijd neemt de vraag naar hun apparaten weer toe. Daarnaast kan het bedrijf nog meer goed nieuws melden. Philips' apneu-apparaten blijken goed verzekerd, en daarom krijgt het bedrijf ruim een half miljard euro aan verzekeringsgeld uitgekeerd. Dat doet goede zaken voor de winst van het bedrijf, en zorgt voor jubelende beleggers. Waar de beleggers minder enthousiast waren, was bij Heineken. Ondanks het EK voetbal kon de bierbrouwer niet aan de verwachtingen voldoen. Volgens Heineken zelf lag dat aan het slechte weer in Noord-Europa. De brouwer heeft wel een oplossing paraat staan, want het gaat meer investeren in hun marketing en sales.  En McDonalds deed eerder nog een poging om klanten te lokken met een maaltijd voor 5 dollar, maar zonder succes. De topman ziet dat zijn klanten vaker thuis de keuken in kruipen, in plaats van naar de Mac komen voor een makkelijke hap. Daarnaast lijkt de fastfoodketen maar niet van een probleem af te komen, want in Amerika worden ze ook nog eens hard geboycot vanwege vermeende banden met Israël.See omnystudio.com/listener for privacy information.

Join Michelle Martin in her daily comprehensive tour of market talking points with Ryan Huang. Today they delve into the latest market action. Asia-Pacific markets are trading lower, driven by overnight Wall Street sell-offs. Netflix's earnings report, TSMC's recent performance, and movements in the automotive industry with Renault, Volvo, and Ford are discussed. The session also covers corporate updates from Abbott Laboratories, Amazon, SATS, Keppel, DBS, and movements in the Straits Times Index. Stay tuned for insights on these developments and more.See omnystudio.com/listener for privacy information.

Welcome back to another exciting clip of Market Mondays! In today's session, Ian Dunlap, Rashad Bilal, and Troy Millings dive deep into the latest stock updates to help you make informed investment decisions. Whether you're a seasoned investor or just starting, this episode is packed with valuable insights.In This Episode*Adobe's AI Advancements:*We start the episode by discussing Adobe and their recent earnings call, which saw the stock price soar by 15%. Adobe unveiled some major advancements in the world of artificial intelligence, but is it too little too late? Ian shares his candid thoughts on Adobe's position in the AI landscape and whether it's worth adding to your portfolio.*Automatic Data Processing (ADP):*Next, Troy brings up ADP, a global technology company specializing in HR, payroll, talent, time, and tax services. While the company has performed well traditionally, is it the best option in its category? Ian provides a nuanced take, putting ADP into the "maybe one day" folder and discussing its pros and cons.*Abbott Laboratories:*We then shift our focus to Abbott Laboratories, a global healthcare company that's down 6% year-to-date. Should you consider dating or dumping this stock? Ian talks about the competition in the healthcare space and under what conditions Abbott Laboratories could be a good pick for long-term investors.*CrowdStrike:*One of the highlights of this episode is the discussion around CrowdStrike, a leader in endpoint security. Up 55% year-to-date, CrowdStrike has managed to establish itself as a front-runner in the cybersecurity field. Ian enthusiastically endorses CrowdStrike, even coining a new phrase – "love bombing" – to describe his investment strategy for this stock.*Newmont Corporation:*On a different note, we explore Newmont Corporation, a major player in the gold, copper, zinc, and lead production sectors. Unfortunately, the outlook isn't too rosy, with Ian giving it a definitive "hell no" due to its high volatility and poor past performance.*Capital One:*Finally, we evaluate Capital One. Despite having a decent run post-pandemic, Ian advises against investing in this financial services company, favoring other options in the banking sector like Chase or BlackRock.Key Takeaways- *Stock Picks:* Understand which stocks are worth dating and which ones you should dump.- *AI & Cybersecurity:* Learn about the leading companies in these rapidly evolving sectors.- *Sector Analysis:* Get insights into healthcare, financial services, and technology stocks.- *Investment Strategies:* Practical tips to help you make better investment choices.If you're enjoying this series, don't forget to like, comment, and subscribe for more episodes!*Timestamps:*- 00:00 - Introduction- 00:04 - Adobe's AI Advancements- 02:01 - Automatic Data Processing (ADP)- 03:35 - Abbott Laboratories- 05:07 - CrowdStrike- 06:26 - Newmont Corporation- 07:21 - Capital One*Join the Conversation:*Have any questions or comments about today's episode? Drop them below, and let's discuss!*Credits:*Hosted by Ian Dunlap, Rashad Bilal, and Troy Millings. *Disclaimer:*The information provided in this episode is for educational and informational purposes only and should not be construed as financial advice. Always consult with a professional before making any investment decisions.#MarketMondays #StocksToWatch #Investing #Adobe #ADP #AbbottLaboratories #CrowdStrike #Newmont #CapitalOne #FinancialFreedom #InvestmentTipsTune in next week for more insights and stock breakdowns from the Market Mondays team!--- Don't miss out on our future episodes; hit that notification bell and stay savvy with your investments!Our Sponsors:* Check out Monarch Money: www.monarchmoney.comSupport this podcast at — https://redcircle.com/marketmondays/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Check out Nascentmc.com for medical writing assistance. visit learnAMAstyle.com for free downloads on medical writing and editing Adbry for Atopic Dermatitis The FDA has approved tralokinumab-ldrm (Adbry) as a 300 mg single-dose autoinjector for moderate-to-severe atopic dermatitis (AD) in adults, offering a more convenient delivery method. Adbry, which inhibits IL-13, was previously approved for adults in December 2021 and for pediatric patients aged 12 and older in December 2023. The approval was granted to LEO Pharma Inc.  Augtyro for NTRK Tumors The FDA has approved repotrectinib (Augtyro) for treating solid tumors with NTRK gene fusions in patients aged 12 and older, based on Phase 1/2 trials showing significant response rates in both TKI-naïve and previously treated patients. The approval was granted to Bristol Myers Squibb, with additional clinical data required to confirm safety and efficacy. Donanemab for Alzheimer's FDA advisors unanimously recommended the approval of donanemab for Alzheimer's disease, emphasizing its efficacy in slowing early-stage disease and manageable risks. Donanemab, targeting amyloid plaques, offers potential advantages over Leqembi with monthly infusions. The FDA decision is expected soon. Iqirvo for Primary Biliary Cholangitis The FDA granted accelerated approval to elafibranor (Iqirvo) for primary biliary cholangitis (PBC) to be used with ursodeoxycholic acid or as monotherapy. Elafibranor targets PPAR-α and PPAR-δ, with Phase 2 trials showing significant biochemical responses. The approval was granted to GENFIT and Ipsen.  Retevmo in Thyroid Cancer The FDA granted full approval to selpercatinib (Retevmo) for advanced or metastatic RET fusion–positive thyroid cancer in patients aged 2 years and older, based on the LIBRETTO-001 trial showing high response rates. The approval was granted to Eli Lilly and Company. OTC Continuous Glucose Monitors The FDA approved Abbott Laboratories' continuous glucose monitoring systems, Libre Rio and Lingo, for over-the-counter use. Libre Rio is for Type 2 diabetes patients not on insulin, while Lingo targets non-diabetic consumers for health improvement. These systems provide real-time glucose monitoring via a smartphone app. Check out Nascentmc.com for medical writing assistance.visit learnAMAstyle.com for free downloads on medical writing and editing  

Michelle Martin leads with news that may have made investors leap for joy before the cold realisation that they could not profit from a glitch. Hear Michelle and Ryan discuss the New York Stock Exchange and stunning drop in Warren Buffett's Berkshire Hathaway stock price. Then we dive into the king of meme stocks, Roaring Kitty, and GameStop. Aso covered are major trades by CEOs of General Motors and Salesforce, and a world tour of market reactions to recent elections in India, Mexico, and South Africa. Finally, we look at local market trends, including a strong start to June for the Straits Times Index, led by DFI Retail.See omnystudio.com/listener for privacy information.

From biotech's rebound to the next frontier for GLP-1 drugmakers, Chendhore Veerappan, PhD, CFA, our health care research analyst, delves into the trends and investment opportunities unfolding in this dynamic sector. Tune in to our latest podcast! As of 30 April 2024, Diamond Hill owned shares of Abbott Laboratories and Roche Holdings AG. SPDR® S&P® Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P® Biotechnology Select IndustryTM Index. The views expressed are those of Diamond Hill as of May 2024 and are subject to change without notice. These opinions are not intended to be a forecast of future events, a guarantee of future results or investment advice. Investing involves risk, including the possible loss of principal. Past performance is not a guarantee of future results.

Susan Finn, PhD, RD, FADA, CEO of Finn/Parks & Associates, is a renowned figure in the food, nutrition, and health sector. She has held leadership positions in the Academy of Nutrition and Dietetics (Past President and Foundation Chair) and worked to promote nutrition support in healthcare during her 30-year tenure with Ross Products Division of Abbott Laboratories. Dr. Finn has received numerous accolades for her contributions to health and nutrition, including appointments by President George W. Bush and Speaker of the House John Boehner. She is also a prolific author and has published in professional journals and co-authored two books. In this episode, we highlight Nutrition Authority: Perspectives on Opportunity and hope you enjoy! Book info: https://www.eatrightstore.org/product-type/books/nutrition-authority-perspectives-on-opportunity

Please visit Nascentmc.com for medical writing assistance for your company. Visit learnAMAstyle.com for free downloads on medical writing and editing Ingrezza for Huntington's: The FDA has approved valbenazine (INGREZZA® SPRINKLE) capsules for adults with tardive dyskinesia and chorea associated with Huntington's disease. This new oral granules formulation provides an alternative for those with swallowing difficulties, maintaining the same dosage strengths as the original capsule form. Valbenazine is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor designed to reduce uncontrollable movements by inhibiting dopamine release. Tivdak for Cervical Cancer: Tisotumab vedotin-tftv (TIVDAK) has been approved for recurrent or metastatic cervical cancer after chemotherapy failure. This approval was based on results from a Phase 3 trial showing a significant overall survival benefit compared to chemotherapy. The approval highlights a significant advancement in treating this aggressive form of cancer, granted to Pfizer and Genmab A/S. Xolremdi for WHIM: Mavorixafor (Xolremdi) has been approved for WHIM syndrome in patients 12 years and older to increase circulating neutrophils and lymphocytes. WHIM syndrome is a rare genetic disorder impairing immune function, and mavorixafor significantly improves cell counts and reduces infection risk. Approval was based on positive results from a double-blind trial and granted to X4 Pharmaceuticals. Esprit Stent for CLTI-BTK: The FDA has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System for chronic limb-threatening ischemia below-the-knee. This is the first approval of its kind in the U.S., offering an alternative to traditional balloon angioplasty. The approval was based on positive outcomes from the LIFE-BTK trial, showing significant disease progression reduction compared to standard care, granted to Abbott Laboratories.  

On March 21, the roughly 70 employees of the Schuler Education Foundation, based in the affluent suburb of Lake Forest, Illinois, were summoned to an emergency all-hands meeting. Over the past two-plus decades, the nonprofit founded and funded by a former president of healthcare giant Abbott Laboratories, Jack Schuler, had spent at least $150 million counseling and tutoring more than 1,800 low-income students from Chicago and Milwaukee-area high schools to help them gain admission to elite colleges; those colleges in turn covered most (if not all) of the students' tuition and other costs.The employees, who first had to certify they wouldn't record anything, were let into a Zoom room where the nonprofit's executive director Joanne Bertsch read from a script announcing that the foundation would shut down on May 24. Everyone would be let go except for a skeleton crew of seven college counselors left to support students through August. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Henry Beverly v. Abbott Laboratories

Nonprofit organizations rely on funding to execute their mission, but steady funding is not always easy to come by. So, what can leaders of nonprofits do to attract attention — and resources — from foundations and corporations with money to give? Many funders want to understand an organization's impact — and quantifying and conveying that impact can take many forms, says Velma Monteiro-Tribble, former director of grants and programs for the Florida Blue Foundation. “People think that there is money lying around; money is tighter today,” she said. “And people are looking at those that really can tell the story... Quantifying, to me, doesn't mean that it's always in data and statistics. It's also through storytelling. And I think that organizations, nonprofits especially, should be in the business of doing that today.” This week on the Health Disparities podcast, hosts Rev. Willis Steele and Dr. Erick Santos join Monterio-Tribble and Al Reid, the former VP of corporate development with Abbott Laboratories. Together, they delve into valuable insights and strategies for attracting funders during challenging times.

On this episode, I was joined by Sayed Badrawi, Pharma/MedTech Investor and Board Member. Sayed walks through starting at Amgen as a bench scientist and transitioning to the commercial side of the Pharma industry. Sayed provides advice for people considering their career paths and emphasizes the importance of gaining expertise in a particular area before making significant career changes. He also highlights some of the challenges and opportunities in the Pharma industry, including the impacts of silos, the complexities of commercialization, and the importance of having a deep understanding of the industry for successful product development and market launch. 00:00 Introduction and Guest Presentation 00:53 Guest's Journey in Medical Device and Pharma Industry 03:10 Transition from Bench Scientist to Business Side 08:31 Commercialization Challenges in Pharmaceutical Industry 13:37 Successes and Failures in the Industry 26:41 Career Advice for Aspiring Professionals: Large vs. Small Companies 32:44 Conclusion Sayed Badrawi has several decades of business, marketing, and scientific experience in pharmaceutical and biotech companies. He was most recently the CEO of PDS Life Sciences, a global provider of software and services used in preclinical research at top-ten pharma companies. He currently serves on the Board of ISI Life Sciences, a startup focused on diagnostics and therapeutics for use in oncology. He is also providing strategy consulting for several early stage start-ups. Previously, he was the Director and Head of new product commercialization at Mitsubishi Tanabe Pharma America, one of the largest pharma companies headquartered in Japan. Other experiences include senior pharma marketing positions at Abbott Laboratories and Eli Lilly. Sayed started his career at Amgen as a research associate and was part of the team to first clone and express erythropoietin, one of the first biotech blockbusters. Sayed has an AB degree in microbiology and immunology from the University of California, Berkeley, and an MBA from the University of Chicago's Booth School of Business.

Welcome back to the Bar Exam Toolbox podcast! In today's episode, we're focusing on one of the most highly-tested topics on the bar exam: Negligence. In particular, we're talking about the different ways in which factual causation can be proved. In this episode, we discuss: Review of the elements of negligence What is factual causation and the five tests that are used to prove it Analyzing two hypos from previous California bar exams Resources: "Listen and Learn" series (https://barexamtoolbox.com/bar-exam-toolbox-podcast-archive-by-topic/bar-exam-toolbox-podcast-explaining-individual-mee-and-california-bar-essay-questions/#listen-learn) California Bar Examination – Essay Questions and Selected Answers, February 2019 (https://www.calbar.ca.gov/Portals/0/documents/admissions/Examinations/Feb2019_CBX_SelectedAnswers.EssayQuestions_R.pdf) California Bar Examination – Essay Questions and Selected Answers, July 2017 (https://www.calbar.ca.gov/Portals/0/documents/admissions/Examinations/Jul2017_CBXSelectedAnswers_EssayQuestions1-5.pdf) Summers v. Tice (https://casetext.com/case/summers-v-tice) Sindell v. Abbott Laboratories (https://wiki.harvard.edu/confluence/display/GNME/Sindell+v.+Abbott+Laboratories) Podcast Episode 186: Listen and Learn – Negligence: Proximate Cause (https://barexamtoolbox.com/podcast-episode-186-listen-and-learn-negligence-proximate-cause/) Download the Transcript (https://barexamtoolbox.com/episode-247-listen-and-learn-negligence-factual-causation/) If you enjoy the podcast, we'd love a nice review and/or rating on Apple Podcasts (https://itunes.apple.com/us/podcast/bar-exam-toolbox-podcast-pass-bar-exam-less-stress/id1370651486) or your favorite listening app. And feel free to reach out to us directly. You can always reach us via the contact form on the Bar Exam Toolbox website (https://barexamtoolbox.com/contact-us/). Finally, if you don't want to miss anything, you can sign up for podcast updates (https://barexamtoolbox.com/get-bar-exam-toolbox-podcast-updates/)! Thanks for listening! Alison & Lee

Abbott Laboratories's Q4 2023 earnings call, unedited

On episode 456 of The Nurse Keith Show nursing and healthcare career podcast, Keith interviews seasoned biopharmaceutical executive Janice Nissen, BSN, MBA, MS and William Soliman, PhD, BCMAS, the Founder and CEO of the Accreditation Council for Medical Affairs (ACMA). In the course of their conversation, Keith and his guests discuss the plethora of career opportunities in the life science industry — including pharma and biotech — that ambitious and curious nurses can take advantage of when seeking new professional avenues of endeavour. Also discussed are the changes that the pharmaceutical industry has undergone in recent years, and how situations around the globe, such as the war in Ukraine, can directly impact the availability of many commonly used medications. Dr. William Soliman is the Founder and CEO of the Accreditation Council for Medical Affairs (ACMA). He is considered by many to be a pharma industry futurist. With over 15 years of experience in the pharmaceutical industry working with several companies such as Merck, Abbvie, Gilead Sciences and Eisai and others, Dr. Soliman is passionate about transforming the industry through benchmarking and technology. ACMA is most well-known for the Board Certified Medical Affairs Specialist (BCMAS) program which is the first and only board certification for MSL and Medical Affairs Professionals in the world. The ACMA also works within the market access space offering the Prior Authorization Certification Specialist (PACS) program and the Biologics & Biosimilars area with the first Board Certification offered in this field. Janice Nissen is a healthcare professional and a seasoned biopharmaceutical executive who has developed commercialization strategies at two multinational pharmaceutical companies, Merck, and Abbott Laboratories. This work included numerous first-in-class products with market leadership and favorable outcomes for patients. She led an enterprise-wide, global strategy of incorporating patient input into the companies' value chain, from discovery through patent expiry, resulting in products that were more relevant, valued, and accessible.  Jan is currently consulting with the NIH Foundation on patient engagement strategies to support their public-private partnerships, and building a first of its kind educational curriculum for nurses interested in a life science career with the Accreditation Council for Medical Affairs. She is also serving as an advisor to Press Ganey on customer experience in clinical trials. Connect with Dr. William Soliman and Janice Nissen: ACMA Dr. Soliman on TikTok Dr. Soliman on LinkedIn NursetoPharma.org Janice Nissen on LinkedIn ----------- Did you know that you can now earn CEUs from listening to podcasts? That's right — over at RNegade.pro, they're building a library of nursing podcasts offering continuing education credits, including episodes of The Nurse Keith Show! So just head over to RNegade.pro, log into the portal, select Nurse Keith (or any other Content Creator) from the Content Creator dropdown, and get CEs for any content on the platform! Nurse Keith is a holistic career coach for nurses, professional podcaster, published author, award-winning blogger, inspiring keynote speaker, and successful nurse entrepreneur. Connect with Nurse Keith at NurseKeith.com, and on Twitter, Facebook, LinkedIn, and Instagram. Nurse Keith lives in beautiful Santa Fe, New Mexico with his lovely fiancée, Shada McKenzie, a highly gifted traditional astrologer and reader of the tarot. You can find Shada at The Circle and the Dot. The Nurse Keith Show is a proud member of The Health Podcast Network, one of the largest and fastest-growing collections of authoritative, high-quality podcasts taking on the tough topics in health and care with empathy, expertise, and a commitment to excellence. The podcast is adroitly produced by Rob Johnston of 520R Podcasting, and Mark Capispisan is our stalwart social media ringmaster and newsletter wrangler.

Dive into the heart of exceptional customer experience in healthcare as we unravel innovative CX strategies at Abbott. Join Lauren Wood on episode #9 of the Experts of Experience podcast as she sits down with Bassem Hanna, Global Head of Customer Experience at Abbott Laboratories. Abbott, a leader in global healthcare, is at the forefront of enhancing customer experience in a complex, rapidly evolving industry.In this episode, Bassem shares his unique approach to customer centricity, cross-functional collaboration, and leveraging AI in the healthcare sector. Discover how Abbott's innovative strategies are shaping the future of customer experience and driving success in the healthcare industry.Bassem shares his insights on navigating the challenges of global customer support, his philosophy on the role of technology in customer service, and his vision for personalizing customer interactions despite industry constraints.If you find this episode enlightening, please rate our show on Spotify and Apple Podcasts. Subscribe Now: https://www.youtube.com/@ExpertsofExperience Imagine running your business with a trusted advisor who has your success top of mind. That's what it's like when you have a Salesforce Success Plan. With the right plan, Salesforce is with you through every stage of your journey — from onboarding, to realizing business outcomes, to driving efficient growth.Learn more about what's possible on the Salesforce success plan website: http://sfdc.co/SalesforceCustomerSuccess (00:00) - Introduction to Bassem Hanna and Abbott(01:07) - Bassem Hanna's Role at Abbott and CX Challenges(02:54) - Key Elements of Successful CX(06:53) - Metrics for Tracking CX Success(08:39) - Data-Driven Customer Insights(10:19) - Empowering Teams and Building Culture(14:01) - AI and Efficiency in Customer Service(17:26) - Innovations and Challenges in Implementing AI(20:33) - Personalization and Data Utilization in CX(24:56) - Navigating Data Privacy in Healthcare(27:55) - Managing Rapid Changes and Global Compliance(28:08) - Quality Management in Customer Support(30:42) - Creating a Positive Team Environment(32:36) - Bassem Hanna's Advice for CX Leaders 

Rollie Calrson is the CEO of Immunexpress, a company that is pioneering technology that can rapidly detect sepsis. Rollie contributed to the success of Abbott Laboratories for 20 years, starting off in R&D, then transitioning to leadership positions in global businesses and start-up ventures. His attraction to start-ups led him to become CEO of Asuragen and then WaferGen Biosystems. In this episode we discuss how he prepared for new opportunities, the benefits of extreme ownership, balancing company vision and mission, alignment of everyone in a company, why sepsis is such a big problem, and what Immunexpress is doing to help clinicians better manage sepsis patients.  Links from this episode:Rollie Carlson LinkedIn https://www.linkedin.com/in/rollie-carlson-ph-d-059074a/Immunexpress  https://immunexpress.com/Support the showConnect with Mastering Medical Device: Website: https://www.masteringmedicaldevice.com LinkedIn: https://www.linkedin.com/company/mastering-medical-device Patrick Kothe LinkedIn: https://www.linkedin.com/in/patrick-kothe Patrick Kothe Twitter: https://twitter.com/patrickkothe Support the show for as little as $3/month: https://www.buzzsprout.com/1286645/support Thanks for listening!

In Re Abbott Laboratories

In this episode of Life Science Success, my guest is Bob Rochelle the Chief Commercial Officer at Cleveland Diagnostics.  Bob is a proven expert in launch, strategy, and marketing for novel healthcare products. His more than 30 years of experience ranges from start-ups such as Exact Sciences and Good Start Genetics to established multinationals such as Abbott Laboratories.   Introduction of Bob Rochelle: The episode of "Life Science Success" features Bob Rochelle, Chief Commercial Officer at Cleveland Diagnostics. Rochelle is recognized for his expertise in launch strategy and marketing for novel healthcare products. Bob Rochelle's Background: With 35 years in the healthcare industry, Rochelle has extensive experience, primarily in diagnostics, working with both pharmaceuticals and startups. His career includes roles in various therapeutic and diagnostic areas, from antibiotics and antihypertensive drugs to genetic disease diagnostics and cancer. Transition to Startups: Rochelle discusses his transition from large corporations like Abbott Laboratories to smaller startups. He emphasizes the appeal of being able to rapidly implement ideas and the challenges of limited resources compared to larger companies. Cleveland Diagnostics and Novel Technology: At Cleveland Diagnostics, Rochelle is involved with a novel platform technology for cancer diagnostics. He highlights the importance of innovative technology and a strong team in his career choices. Insights on Cancer Diagnostics and Career Lessons: Rochelle shares insights on the evolution of cancer diagnostics, emphasizing the importance of specificity and sensitivity in tests like isopsa for prostate cancer. He reflects on lessons learned throughout his career, including the significance of diverse perspectives in small companies and the challenges of navigating healthcare reimbursement systems.

On this episode, I was joined by Martin Van Trieste, Author of Protecting the Patient at All Costs: The Drug Watch Dogs and is the Former Chief Quality Officer at Amgen and Former CEO at Civica Rx. Martin and I discuss: - Protecting the Patient at All Costs - Quality Leadership and being a Chief Quality Officer in Big Pharma - Supply Chain Security - Generic Drugs and Shortages Martin Van Trieste is an accomplished entrepreneur, board governance expert, executive coach and biopharmaceutical executive. Martin Van Trieste is the Former President and CEO of Civica Rx. Prior to joining Civica Rx, he worked with Amgen, a leading biotechnology company and also previously served as vice president of worldwide quality for Bayer Healthcare's Biological Products Division and vice president of quality assurance for the Hospital Products Division for Abbott Laboratories. Van Trieste has also taken on ventures of his own. He's the founder of Rx-360, an international nonprofit organization that enhances patient safety by increasing security and quality in the biopharmaceutical supply chain. He has also served as the chairman of the Parenteral Drug Association (PDA) Board of Directors and was honored with the 2020 Joseph B. Sprowls Lecturer award. 

Abbott Laboratories, Q3 2023 Earnings Call, Oct 18, 2023

On this day in legal history, October 5, 1941, Supreme Court Justice Louis Brandeis died at the age of 84. Louis Brandeis was born on November 13, 1856, in Louisville, Kentucky. He graduated from Harvard Law School at the age of 20 with the highest grade point average in the school's history. In 1890, he gained recognition for developing the "right to privacy" concept through an article in the Harvard Law Review. Brandeis was a prominent figure in the antitrust movement and was known for his resistance to monopolies, particularly in the New England railroad sector. He also advised Woodrow Wilson and was critical of large banks and powerful corporations in his writings.Brandeis became active in the Zionist movement, viewing it as a solution to antisemitism in Europe and Russia. He was often referred to as the "People's Lawyer" and took cases without pay to focus on broader issues. He set a new precedent in evidence presentation with the "Brandeis brief," which utilized expert testimony from various professions. In 1916, President Woodrow Wilson nominated him to the U.S. Supreme Court, making him the first Jewish member. His nomination was met with significant opposition but was eventually confirmed by the Senate.During his tenure on the Supreme Court from 1916 to 1939, Brandeis became one of the most influential justices in history. He was known for his strong defenses of freedom of speech and the right to privacy. However, he has been criticized for not addressing issues related to African-Americans and for supporting racial segregation in some cases. Brandeis retired from the Supreme Court on February 13, 1939, and passed away on October 5, 1941, in Washington, D.C.The U.S. Court of Appeals for the Ninth Circuit is set to hear a case concerning Meta Platforms Inc., the parent company of Facebook, and its alleged preference for hiring workers on H-1B visas. The case, brought by appellant Purushothaman Rajaram, questions whether U.S. citizens are a protected class under Section 1981 of the 1866 Civil Rights Act. A federal district court previously dismissed the case, stating that the act does not cover "reverse discrimination" claims. Rajaram's lawyers argue that Section 1981 should be broadly interpreted to include U.S. citizens, while Meta contends that the law has traditionally been applied narrowly to race or alien status.The case also brings into focus Meta's hiring practices. The company was one of the top H-1B employers in fiscal year 2022, with over 1,500 approved petitions for new workers. Rajaram, a naturalized U.S. citizen, claims that Meta's hiring policies favor workers on H-1B visas over equally or more qualified U.S. citizens. If Rajaram wins, it could discourage companies from prioritizing H-1B workers over U.S. citizens.The Department of Justice and the Department of Labor have previously scrutinized Meta's H-1B hiring practices. The company settled those claims by paying over $14 million in civil penalties without admitting any wrongdoing. Rajaram's lawsuit aims to address citizenship discrimination in hiring more broadly, not just positions earmarked for visa workers.Experts note that the structure of the H-1B program itself may contribute to competition between visa holders and U.S. workers. Companies have little incentive to pay H-1B workers more than the prevailing wage, leading them to file as many petitions as possible for minimally qualified candidates. The case began with oral arguments yesterday. Meta's H-1B Hiring Spurs Ninth Circuit Look at Citizenship BiasA federal judge has ordered the Centers for Medicare & Medicaid Services (CMS) to withdraw a Trump-era rule concerning copay assistance programs. The rule had been challenged by patient advocacy groups, including the HIV+Hepatitis Policy Institute and the Diabetes Leadership Council, who claimed it allowed health plans to increase out-of-pocket prescription drug costs. Judge John D. Bates stated that the rule conflicted with the Affordable Care Act's definition of "cost-sharing" and must be set aside.The 2020 rule had stated that pharmacy benefit managers (PBMs), who manage prescription drug benefits for insurers, were not required to count drugmaker copay assistance toward patients' out-of-pocket costs. The patient groups argued that this allowed PBMs and health plans to collect funds from both patients and drugmakers without using the money to ease the financial burden on patients.The ruling is seen as a victory for these patient advocacy groups, who filed the lawsuit in August 2022. Carl Schmid, the executive director of the HIV+Hepatitis Policy Institute, expressed satisfaction with the court's decision and called on the Biden administration to enforce it immediately.The advocacy groups are backed by pharmaceutical companies like Pfizer, Johnson & Johnson, Abbott Laboratories, Eli Lilly & Co., and Merck & Co. While these companies can offer assistance to patients in commercial plans, such programs are prohibited in government-funded health insurance due to the Anti-Kickback Statute.The Department of Health and Human Services (HHS) had previously argued that manufacturer coupons could add long-term costs to the healthcare system, outweighing the short-term benefits. Both the Department of Justice, representing CMS and HHS, and a CMS spokesperson declined to comment on the ruling. The case is titled HIV & Hepatitis Policy Inst. v. Dep't of Health & Human Servs. and was filed on September 29, 2023.Judge Strikes Down Trump-Era Medicare Copay Assistance Rule (1)The trial of Sam Bankman-Fried, founder of the collapsed FTX cryptocurrency exchange, has begun with both sides presenting differing views on the reasons behind the company's failure. Bankman-Fried is accused of using FTX customer funds to support his hedge fund, Alameda Research, as well as for personal expenditures like luxury real estate and political donations. He has pleaded not guilty to these charges. His defense lawyer, Mark Cohen, portrayed him as a "math nerd" from MIT who may have overlooked risk management but did not engage in theft.Prosecutor Thane Rehn, however, argued that Bankman-Fried took more than $10 billion from FTX customers and used the funds to build his empire through fraudulent means. Rehn stated that the defendant "doubled down" on risky investments when Alameda began losing money. The prosecution plans to call three former associates of Bankman-Fried, all of whom have pleaded guilty and agreed to cooperate, to testify against him.The defense suggested that these witnesses might retrospectively portray Bankman-Fried's decisions as deceitful, even though they had agreed with those decisions at the time. The jury for the trial includes a diverse group of individuals, including a retired investment banker, a school librarian, and a train conductor. Bankman-Fried has been in detention since August 11 for likely tampering with witnesses.The trial comes nearly a year after the collapse of FTX, which had a significant impact on financial markets and damaged Bankman-Fried's reputation. It promises to offer an inside look into the operations of a cryptocurrency exchange and the legal boundaries within which such businesses operate.Sam Bankman-Fried trial jurors hear competing explanations for FTX collapse | ReutersJudge Arthur Engoron, overseeing Donald Trump's civil fraud trial in New York, expressed frustration with Trump's legal team for what he termed as "ridiculous" and redundant questioning of a witness. The trial is centered on allegations by the New York attorney general's office that Trump inflated his net worth by billions to secure better loan and insurance terms. Engoron, who is the sole decider of the case's outcome, has already disciplined Trump's lawyers for making "frivolous" arguments.Earlier, Engoron had imposed a gag order on public comments about court staff after Trump criticized the judge's top law clerk on social media. Trump, who has been present in court, has consistently attacked both the judge and New York Attorney General Letitia James, labeling them as "corrupt" and the case as a "sham."Last week, Engoron ruled that Trump, his two adult sons, and 10 of his companies had committed fraud. He revoked the business certificates for key assets, including Trump Tower and 40 Wall Street, and said he would appoint receivers for their dissolution. Trump's lawyers have appealed this decision.The trial mainly concerns the assessment of damages, with James seeking at least $250 million in fines and various bans against Trump and his sons from conducting business in New York. The trial is expected to continue until mid-December. Trump also faces other legal challenges, including four criminal indictments and a civil damages trial scheduled for January. He has denied wrongdoing in all cases.Judge chides Donald Trump lawyer's 'ridiculous' questioning in civil fraud trial | Reuters Get full access to Minimum Competence - Daily Legal News Podcast at www.minimumcomp.com/subscribe

This episode's Community Champion Sponsor is Catalyst. To virtually tour Catalyst and claim your space on campus, or host an upcoming event: CLICK HERE---Episode Overview: During this episode, we spend time with Dr. Agim Beshiri, Chief Medical Officer of Nutromics, an international leader pioneering continuous diagnostic monitoring to transform personalized care. Bringing over 20 years of clinical and industry expertise, Agim is driven to advance patient-centric precision medicine. While together, Agim shares how Nutromics utilizes synthetic DNA sensors for real-time, first-order molecular recognition. Additionally, Agim unpacks the future of scaling personalized treatment through continuous multiplexed monitoring. We also discuss reinventing antiquated blood testing methodologies and paradigm shifts enabling preventative intervention. Join us as Agim outlines a vision for mimicking implanted diagnostic tools across diverse disease states and to gain inspiration from his dedication to elevating global standards of care through innovative diagnostics. Let's go! Episode Highlights:Agim brings deep medical affairs experience to transform diagnostic testingHow Nutromics uses synthetic DNA sensors for continuous, multiplexed monitoringWays in which Nutromics enables real-time precision dosing adjustments and early interventionsAgim envisions scaling continuous diagnostics across diverse disease statesHow Agim exemplifies commitment to profoundly advancing personalized medicine About our Guest: Agim Beshiri, M.D., is the Chief Medical Officer (CMO) at MedTech startup Nutromics. His passion is in elevating the standard of care for all patients. With over 20 years' experience in the IVD field both in the clinical setting and industry. Dr Beshiri developed methods and collaborations that enabled patient-centric application of diagnostics addressing underserved patients in disease states from cardiology to oncology.A leading industry expert in developing a medical affairs organization and driving medical research and education. With a broad background in internal medicine, hematology, general cardiology, and laboratory medicine, Dr Beshiri initiated and collaborated on research programs resulting in over 800 research collaborations and over 1000 publications.Prior to Nutromics, Dr Beshiri was Senior Medical Director at Abbott Laboratories where he developed supporting their Diagnostics organization for over 16 years. His clinical experience includes the Brooke Army Medical Center in Texas, the 452nd Combat Support Hospital in Wisconsin and Aurora/Advocate Clinical Laboratories in Wisconsin and Illinois, and South-eastern Europe.Dr. Beshiri is a member of several organizations, including the American Medical Association, American Heart Association, European Society of Cardiology, International Society for Laboratory Hematology, European Hematology Association, American Society of Hematology, and American Society of Clinical Oncology. He has also served on guideline subcommittees for the Clinical and Laboratory Standards Institute.Links Supporting This Episode:Nutromics Website: CLICK HEREDr. Agim Beshiri LinkedIn page: CLICK HERENutromics Twitter page: CLICK HERE Mike Biselli LinkedIn page:

Episode: Designing Dollars with Cedrick LaFleur Host: Nikki Klugh Welcome to Create Your Sacred Space Podcast with Nikki Klugh. the podcast that unveils the soul of architecture and design. Join us as we explore the passion, creativity, and purpose behind the most inspiring spaces and projects and dive deep with those who create them consistently. I'm your host, Nikki Klugh, and I'll be your guide as we journey through the hearts and minds of sacred space architects and designers who are driven by compassion and authenticity. _________________________________________________ Cedrick LaFleur Bio: Cedrick LaFleur is a motivational and empowering Senior Executive with more than 30 years of success across the healthcare sales and leadership industry. He is the Chief Executive at LaFleur Leadership Institute, where he has created a successful company that delivers workshops, seminars, keynote speeches, and coaching for organizations focused on leadership development. Cedrick is an Executive Director with John Maxwell Team, his responsibilities include Executive Leadership Training, Coaching, and Keynote Speaking internationally. Recently he was in Costa Rica helping lead a government leadership transformation for Costa Rican government. In addition, Cedrick is a Dave Ramsey Certified Master Financial Coach, where he provides financial literacy training to individuals and organizations across the U.S. Cedrick is the Chairman of the Executive Leadership Circle, which is a private organization where thought leaders discuss and address global topics. Finally, he serves as Founding Partner and President of Lake Charles Education Collaboration, Inc. a 501c3 Education Based Think Tank. Their focus is to help low-performing and failing schools improve academic outcomes. Cedrick is also a certified Ramsey Solutions Master Financial Coach. Cedrick recently retired as Regional Sales Manager, from Abbott Laboratories after serving for 22 years. Cedrick attained his BA in Organizational Management from Warner Southern College and his AS in Laboratory Science from Eastern Florida State College. He served as a Medical Technologist for 7.5 years with the US Air Force and is a certified Medical Technologist(Clinical Laboratory Scientist) by American Medical Technologists. Cedrick has been married to Tammie for 37 years; they have two children, TreKessa (36 yrs old) and Patrick (30 yrs old). __________________________________________ Thank you for being a part of our heart-centered community, and until next time, may your life be filled with sacred spaces that reflect the beauty of your soul. Remember, FIRST We shape our buildings; thereafter they shape us.

In the latest episode of the Empowerography Podcast, my guest is Jean Marie Russo. Family is everything. Jean Marie embraces her Italian and German heritage. She gives gratitude to her loving parents who are with her in spirit. The greatest success she feels she has already achieved: the miracle birth of her son. It is with special gratitude and recognition given to Dr. Mario Garretto, the GI Specialist who saved both her and her unborn child's life and to Abbott Laboratories because of the need of the feeding tub and Ensure she is here today to give the testimonial. Jean Marie took early retirement after caring for both parents for 20 years while maintaining a 25+ year career in the global corporate pharmaceutical world excelling in Global Meeting & Event Planning, Customer Service, HR, Diversity, Training and Development. An entrepreneur of: Speaking of Success, Inc.; Pearls of Wisdom, Inc.; and It's About People International, Inc., a Global Speaker and Matchmaker for Global Influential Speakers matching each of these exceptional professionals with Organizations, Corporations, Associations, focusing on specific platforms and categories in the Corporate sector, Health & Wellness, Body, Mind and Spirit, changing lives globally.. In this episode we discuss speaking of success, being a trailblazer, success, networking and that people are truly everything.   Website - https://www.speakingsuccessinc.com IG - https://www.instagram.com/jeanrusso.123/ FB - https://www.facebook.com/speakingofsuccessinc LinkedIn - https://www.linkedin.com/in/jeanmarierusso-speakingofsuccessinc/ Accelerated Entrepreneur Conference - https://www.acceleratedentrepreneur.org The Art of Saving Time & Money Book - https://bestkeptsecrets.drbglobal.net   In this episode you will learn: 1. Why we all as people must have a platform. 2. The importance of connection and people in our lives. 3. Why you should never every underestimate the power of YOU.   "I felt like I was a pioneer looking back now because It brought to the attention of the corporation that to have a person that had potential and was of high caliber, it was worth it." - 00:05:16 "It is important for a speaker to recognize the value Of your voice."- 00:29:44 "Never ever underestimate the power of you know that you have. Love and influence beyond your imagination." - 01:02:09   THE WORLD needs to hear your message and your story. Don't deny the world of that gift within you that the universe has gave to you. Someone out there needs to hear your story because it will support them in feeling hope, inspired and even transformed. Want to discover how I help my clients get out of their own way, show up and confidently share their message? I would like to invite you to check out my FREE MASTERCLASS REPLAY Start Your Own Podcast: Idea to Implementation Watch Here - https://www.youtube.com/watch?v=H7iItDG4qaI

Please enjoy this pre-recorded session from our 2023 Student Conference. "Beyond the Head of the Bed" - Jennifer BanekJennifer Banek is a CRNA who resides in Libertyville, IL. Ms. Banek has a Bachelor of Science in Biology and prior to becoming a CRNA, she worked in drug research for Abbott Laboratories. She graduated with her Master of Science in Nursing from DePaul University and earned her anesthesia certification from the NorthShore School of Nurse Anesthesia, Chicago, in 2012. Jennifer is licensed to practice in both Illinois and Wisconsin and has practiced in a variety of clinical settings in both states. In 2020, she was elected to serve 700K Lake County Illinois residents as the coroner. She has served in professional leadership roles in both state and national capacities. Currently, she is on the American Association of Nurse Anesthesiology's Board of Directors. Ms. Banek has served in the United States Army Reserves for approximately 14 years. She is currently the Commander for the 1MCTD, which trains at Ft. Sill, OK. Jennifer's partner is also a CRNA and a service member. Together, they have four grown children.Thank You to Our 2023 Conference Sponsors: Independent Anesthesia ServicesWellspan HealthLocums At HeartAssociated Anesthesiologist Support the showTo access all of our content, download the CORE Anesthesia App available here on the App Store and here on Google Play. Want to connect? Check out our instagram or email us at info@coreanesthesia.com

Abbott Laboratories, Q2 2023 Earnings Call, Jul 20, 2023

Alvin Schexnider is an emancipatory designer and a business operations strategist who helps institutions become more effective, just, citizen-centered, and innovative. He has 15 years of experience in leadership across design, strategy, equity, and business operations in the government, nonprofit and for-profit spaces. Currently he is a part of Capital One's Equity and Design team as a senior equity design strategist. Outside his day-to-day work, he runs GraffitiVersal, an organization that makes resources to inspire, elevate, and catalyze change. GraffitiVersal's latest release is called A Continuum of Freeing Design and Vigorous Futures, a card deck detailing an approach for designing for both equitable and just outcomes in the present, and for thriving worlds in the future. We talk about bringing human-centered design to operations and human resources.   Listen to learn about: Alvin's roundabout road into design Alvin's experiences at the Greater Good Studio Using design at the Illinois Department of Health during the COVID-19 pandemic Alvin's role as Senior Equity Design Strategist at Capital One   Our Guest Alvin (he/him) is a designer, futurist, strategist, and illustrator. He's a right brain / left brained DesignOps leader, with 10 + years of tri-sector people management, who uses foresight and equity to build and vitalize impactful organizations. He leverages his 15 years of experience and leadership across strategy & business operations, multidisciplinary design (service design, human-centered design, equity design), and org change to drive concepting, adoption, and implementation of major initiatives. At present, he is a Manager, Design Practice & Equity Design on Capital One's Experience Strategy & Operations Team; previously, he was Sr. Equity Design Strategist in its Equity by Design Program. Before this role, he was Chief People Officer of the Illinois Department of Human Services (IDHS - agency budget of $9 Billion), focused on improving the experience of 14,000 staff while leading a department of 130 people, and before that, he was also Senior Operations Lead for IDHS focusing on strategy, bizops, and service design projects. Alvin began to build capacity in human-centered design as the first Director of Design Operations at Greater Good Studio, a human-centered design firm that works with global foundations, government agencies, and national NGOs. Outside of his day job, Alvin is also Founder & Organizer of GraffitiVersal — an emancipatory lab using design, art, foresight, & Afrofuturism for change. GraffitiVersal's Racial DeckEquity Cardset & Continuum of Freeing Design & Vigorous Futures CardDeck have been used at organizations such as: Meta, LAB at OPM, Univ. of Chicago, and Slalom Consulting. He's also the author of A Kids Book About Radical Dreaming (via A Kids Co.) and is currently writing & illustrating his first Afrofuturist graphic novel for middle schoolers through the Sequential Artists Workshop's Graphic Novel Intensive. Besides hanging with his partner and 2 kids, you'll find him reading N.K. Jemisin or a Black Panther comic book.   Show Highlights [00:39] Alvin's love of art and storytelling started early, as a kid creating his own comics. [05:06] Starting college as a PolySci major with plans to be a lawyer. [07:18] The moment Alvin realized he didn't want to pursue law as a career. [07:56] Moving on to business management studies, and his time in Beijing. [09:02] Starting his business career at Abbott Laboratories and returning to China. [13:21] Sidestepping away from for-profit into mission-driven and non-profit spaces. [15:14] Realizing he had a knack for business operations and systems thinking. [16:47] How his time as Director of Operations at Greater Good Studio transformed his thinking and started him on his own path into design. [21:07] Immersing himself in design spaces and in learning design. [21:57] Taking all he'd learned about human-centered design into his next job — COO of Erie Neighborhood House Services. [23:52] Getting recruited to work for the Illinois Department of Human Services. [27:10] During the COVID-19 pandemic, Alvin used design to help shape the department's response. [29:19] Redesigning policies and spaces to keep staff healthy as essential workers. [35:27] Taking over as the head of HR for the department, and working on improving employee experience. [38:33] Alvin's current role as the Senior Equity Design Strategist for Capital One's Equity by Design team. [43:06] You don't have to be an official designer to use design in your work.   Links Alvin Schexnider on LinkedIn Alvin Schexnider on Medium GraffitiVersal GraffitiVersal on Instagram A Kids Book About Radical Dreaming (A Kids Co Publishing) by Alvin Schexnider - recently released! Wakanda Forever - A Film Review - Human Futures Magazine AIGA Chicago Podcast - Designing For: Equity Interview with Slalom Consulting Continuum Deck of Freeing Design & Vigorous Futures Traveling through the spacetime continuum to escape racism   Books Recommendations Kindred, by Octavia Butler We Do This Til We Free Us, by Mariame Kaba Black Panther: A Nation Under Our Feet, by Ta Nehisi Coates Design Justice: Community-Led Practices to Build the Worlds We Need, by Sasha Costanza-Chock This is Service Design Doing, by Marc Stickdorn, Markus Hormess, and Adam Lawrence Afrofuturism: The World of Black Sci-Fi and Fantasy Culture, by Ytasha Womack Far Sector, by N.K. Jemisin Employee Experience: Develop a Happy, Productive and Supported Workforce for Exceptional Individual and Business Performance, by Ben Whittier Emergent Strategy: Shaping Change, Changing Worlds, by Adrienne Maree Brown Good Services: How to Design Services that Work, by Louise Downe Drawn Together, by Minh Lê and Dan Santat   Other Design Thinking 101 Episodes You Might Like Designing for the Greater Good, Strategy + Design Thinking, and Measuring Design Thinking with Jeanne Liedtka — DT101 E1 Critical and Emancipatory Design Thinking with Lesley-Ann Noel — DT101 E57 5.5 Things Every Designer Should Know About: The Opioid Overdose Epidemic (Part 1) with Stacy Stanford — DT101 E102

Simply put, the automotive industry can be stressful. Trying to balance that stress and other triggers amidst pressure to sell vehicles, manage apprehensive customers and navigate a tough economic climate is challenging. In this episode, we discuss methods for understanding the root of our emotions and triggers, managing stress, giving feedback to staff and more. Discover the tactics needed to elevate leadership at your dealership with expert Dr. Scott Livingston, president of Livingston Consulting Group. In this episode you'll hear: What emotional intelligence is and how to balance it in the automotive industry When stress can be used to your advantage in your dealership work Methods for managing triggers and knowing when stress turns bad Using Pattern Interrupt to diffuse situations Extrinsic and intrinsic motivators and how that impacts your team How to listen to and understand your team's emotional needs Why people ultimately follow leaders The three-part process of feedback and how to give feedback to your staff At Livingston Consulting Group, a leadership development organization, Dr. Scott Livingston, specializes in leader development and executive coaching. He has worked with leaders from Abbott Laboratories, JM Family Enterprises (JM&A Group's parent company), Dover Manufacturing and many more. Dr. Livingston uses emotional intelligence to improve the relational skill and performance execution of leaders in organizations as this provides a measure of self-awareness, which helps enhance leader relationships and decision-making capabilities. Scott has over 30 years of experience in leadership roles, some of which were held at Eli Lilly where he was a two-time winner of the Leadership Coaching Award and four-time winner of the distinguished Master Performer award. He is also an Adjunct Professor of Executive Coaching and Leadership Development at Indiana Wesleyan University and Concordia University Irvine. For more about Dr. Scott, visit his website: https://drscottlivingston.com/ Like this episode? ⁠⁠⁠Check out JM&A Insider⁠⁠⁠ for more content like this.

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: learning more about Lilly's plan to lower the price of some insulins, Abbott's Libre 2 and Libre 3 get FDA approval to work with automated insulin delivery systems like Control IQ and Omnipod 5, Medicare expands coverage of CGMs for people with type 2, an old blood pressure medication shows promising results in a T1D study, and more!   Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza  Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by Athletic Greens XX Insulin prices https://www.statnews.com/2023/03/06/eli-lilly-insulin-medicaid-rebates/ Drugmaker Eli Lilly & Co. on Wednesday said it will cut prices of its most commonly prescribed insulins by 70% and cap monthly out-of-pocket costs at $35 at certain retail pharmacies for people who have private insurance.   Lilly will list its Lispro injection at $25 a vial effective May 1 and slash the price of its Humalog and Humlin injections by 70% starting in the fourth quarter.   The announcement comes amid growing federal pressure to lower the cost of insulin. The Inflation Reduction Act capped insulin prices for Medicare beneficiaries at $35 per month but did not protect people with private insurance or who don't have coverage from higher prices. Eli Lilly would've had to pay Medicaid about $150 for each vial of insulin used in the program if it hadn't dramatically cut the list prices for some of its older products this week. The company was about to run into a Medicaid penalty for raising the price of it's drugs faster than the rate of inflation. https://www.cnbc.com/2023/03/01/lilly-cuts-insulin-prices-70percent-cap-prices-at-35-per-month-for-private-insurance.html XX The FDA has cleared Abbott's Freestyle Libre 2 and Libre 3 continuous glucose monitors (CGM) for integration with automated insulin delivery (AID) systems. These devices have also been cleared for younger children, extended wear time, and for use during pregnancy.   The FDA on March 6 cleared Abbott's Freestyle Libre 2 and Freestyle Libre 3 CGM for use with automated insulin delivery (AID) systems.   AID systems connect a CGM, insulin pump, and smartphone to automatically adjust insulin dosing in real-time in response to changing glucose levels. These systems have been demonstrated to help many people with diabetes improve their time in range and reduce the time spent thinking about managing glucose each day.   With this new clearance from the FDA, Libre 2 and 3 CGMs and the connected smartphone app will soon integrate with insulin pumps to adjust insulin dosing.   Freestyle Libre 2 and Libre 3 CGMs were previously cleared for use by people with diabetes ages 4 and older. Freestyle Libre 3, cleared in the United States in May 2022, is compatible with both iOS and Android smartphones. Among several upgrades made from Libre 2, Libre 3 no longer requires users to manually scan their device with their smartphone to see glucose levels – data is sent to the mobile app automatically.   In the announcement, Abbott said the device has also been cleared for an extended wear time of 15 days, for use by children as young as age 2, and for use during pregnancy by women with type 1, type 2, or gestational diabetes.   Current users of Libre CGMs should note that the devices available now cover people with diabetes ages 4 and older, can be worn for 14 days, and are not cleared for use during pregnancy. According to Abbott, the modified Libre 2 and 3 sensors will be available in the U.S. later this year. https://diatribe.org/fda-clears-freestyle-libre-2-and-3-use-automated-insulin-delivery XX Medicare will cover continuous glucose monitors for a broader group of patients, starting in April, according to an updated policy published by the Centers for Medicare and Medicaid Services.   The policy change included broader language and also came earlier than expected, making it a “welcome surprise,” and could double the market for the devices, J.P. Morgan analyst Robbie Marcus wrote in a research note.   Dexcom and Abbott Laboratories had expected coverage to start in mid-year.   In an earlier draft of coverage guidelines, CMS had suggested covering the devices for people with diabetes who take daily insulin, or who have a history of problematic hypoglycemia. Now, the policy includes people with non-insulin treated diabetes and a history of recurrent level 2 or at least one level 3 hypoglycemic event.   “At first glance, it seems that the finalized CMS language is broader and no longer includes daily insulin language,” Marcus wrote.   The policy change could open up a bigger opportunity for broader coverage by commercial insurers over the next year or two, he added. Currently, just 25% of people with Type 2 diabetes who are intensive insulin users (taking multiple shots per day) use a CGM. Covering people who take basal (daily) insulin could double the U.S. market opportunity of about 2 million people with Type 1 diabetes and 2 million people with Type 2 diabetes who are intensive insulin users, a group currently covered by CMS, Marcus wrote. https://www.medtechdive.com/news/Medicare-CGM-coverage-Dexcom-abbott-ABT-DXCM/644019/ XX Bigfoot Biomedical receives FDA clearance for the Android mobile app for Bigfoot Unity. The mobile app allows users to input and review therapy recommendations from healthcare professionals. Users can also access a glanceable display of their current glucose range and receive real-time alerts.   Last month Bigfoot sold its closed-loop automated insulin delivery (AID) system technology to Insulet. CEO Jeffrey Brewer said he has confidence in the makers of the omnipod to utilize Bigfoot's “great asset” in its focus on simplicity and ease of use for pump users. He said the limited rollout generated “great data” to support Bigfoot Unity in the type 2 population. That includes ease of use, especially for people who might not be tech-savvy.   The big focus for Bigfoot Biomedical, Brewer explained, remains the pharmacy channel. He said the company is currently in discussions with Express Scripts, Optum and CVS to utilize their wide reach. Brewer said that getting an agreement with one or more of those companies will enable a more broad launch this year. By wrapping the insulin delivery around CGM, Bigfoot Biomedical believes it can address the type 2 market in a new way.   https://www.massdevice.com/bigfoot-biomedical-next-steps-diabetes-management/ XX Although the use of diabetes technology has increased across all racial and ethnic groups, inequities persist, according to research published in the Journal of Endocrinology & Metabolism. In the United States, race and ethnicity have been associated with inequities in diabetes treatment and outcomes. Non-Hispanic Black and Hispanic indi- viduals with type 1 diabetes (T1D) have higher hemoglobin A1c (HbA1c), higher rates of severe hypoglycemia and dia- betic ketoacidosis, and are more likely to visit emergency departments and hospitals than individuals with T1D who identify as non-Hispanic White.   Researchers used a version of Optum's deidentified Clinformatics Data Mart to select Medicare Advantage beneficiaries with T1D between January 1, 2017, and December 31, 2020.   Investigators found that overall, use of an insulin pump, a CGM, both insulin pump and CGM, and either insulin pump or CGM increased during the 4-year study period When evaluating the data by racial and ethnic group, investigators found that the prevalence of each outcome did increase; however, “within each annual cohort and outcome, there were significant differences between racial/ethnic groups,” with gaps in prevalence between White individuals and individuals of other races and ethnicities remaining “generally increase[ing] or remaining stable” between 2017 and 2020.   When evaluating data from the 2020 cohort, there were significant differ- ences noted in the use of insulin pump and/or CGM technology based on demographic and socioeconomic factors.   According to the researchers, the “persistent inequities” in diabetes technology access found in the current study have implications “not only for patients and providers, but also for health care systems and policymakers” and require multiple policy changes to improve equitable access.     https://www.drugtopics.com/view/racial-ethnic-inequities-persist-in-diabetes-care XX The CLVer study tested whether improved blood glucose control using a hybrid closed loop insulin pump (also known as an automated insulin delivery or AID system) and/or verapamil preserves beta cell function one year after diagnosis.. The trial showed that verapamil, but not better blood glucose control, improved beta cell function over the year-long study.   In October, the FDA approved the drug Tzeild (teplizumab) for people with diabetes antibodies but who did not yet have type 1 diabetes. This therapy was the first approved medicine to delay the onset of type 1 diabetes by an average of 2 years.   The CLVer study offers further hope for researchers by showing that another medication can have additional impact in type 1 diabetes, and lays the groundwork for further study. By seeing preserved c-peptide levels in the study participants, the trial demonstrated that taking verapamil improved beta cell function.   Additionally, although AID users had greater time in range of 78% compared to non-users' 64%, which is a 3.4 hour/day difference, the trial found that AID did not provide a significant improvement in insulin secretion. This study was partially funded by JDRF   “Safe, effective therapies are urgently needed to delay disease progression in people recently diagnosed with type 1 diabetes,” said Dr. Sanjoy Dutta, chief scientific officer at JDRF. “This is the second trial showing that verapamil, a cheap and widely used blood pressure medication, can preserve beta cells in the new onset period. The CLVer trial moves us one step closer to our goal of having disease modifying therapies widely available for people with type 1 diabetes.” https://diatribe.org/impressive-results-show-verapamil-preserves-insulin-producing-cells-newly-diagnosed-type-1-diabetes XX Some advances in cell transplantation to treat type 1: Vertex gets FDA clearence for their application to study VX-264, a stem cell-derived, pancreatic islet cell therapy encapsulated into an immunoprotective device with the potential to treat type 1 diabetes (T1D). The VX-264 program does not require the use of immunosuppression, which may broaden the population of people with T1D that this investigational therapy could reach. This clearance means they can begin clinical trials. AND Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that the first two patients in the second cohort of its active U.S. Phase 1/2 clinical trial for the treatment of type 1 diabetes (“T1D”) and hypoglycemia unawareness (the “T1D Study”) received their first islet transplant into the higher capacity 10-channel Cell Pouch™.   These patients will be monitored for safety and efficacy for three months after which a second dose of islets is anticipated to be transplanted in accordance with the protocol. Additionally, a third enrolled patient has now been implanted with the higher capacity Cell Pouch and awaits islet transplant in the coming weeks. While they are working towards not using immunosuppression, the patients in the current trial do still require immunosuppression to start after implantation of the Cell Pouch SystemTM   https://www.businesswire.com/news/home/20230308005894/en/Vertex-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-VX-264-a-Novel-Encapsulated-Cell-Therapy-for-the-Treatment-of-Type-1-Diabetes https://finance.yahoo.com/news/sernova-announces-initial-islet-transplantation-120000700.html?guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAH6NwHdjldrxbueuanlpUGXou6yHP2dKNpYXN31GEMLWCyhkJkgwlhn9ScIDMTX5GGtf5V242uN3EvZzFtTd56z0YZaQgOss37DT2dksdasEONxWa7OOdgnWvDlwUd0-s2RPyMTPi1sw8z08CK6DUMLIrrA6dmCDZeozlwos_CDB XX Two classes of drugs prescribed off-label for some patients with Type 1 diabetes can provide significant benefits but also come with health concerns, according to a study by UT Southwestern Medical Center researchers. The findings, published in The Journal of Clinical Endocrinology & Metabolism, provide a rare view of real-world use of these medications, which are growing in popularity among patients with Type 1 diabetes as adjuvants to insulin. Type 1 diabetes is universally treated with insulin injections. However, explained Dr. Lingvay, because only a fifth of patients with Type 1 diabetes in the U.S. achieve the blood sugar control that the American Diabetes Association recommends, doctors are increasingly prescribing medications known as glucagon-like peptide-1 receptor agonists (GLP-1RAs) and/or sodium-glucose cotransporter-2 inhibitors (SGLT2is) to help patients reach this goal. Furthermore, both classes of medications have been shown in patients with Type 2 diabetes to decrease the risk of cardiac and renal events and help promote weight loss, effects that also would greatly benefit patients with Type 1 diabetes. However, the risk-benefit ratio of these medications has not been fully vetted in this patient population.   In fact, both classes of drugs have been associated with increased risk of severe hypoglycemia and DKA when used in patients with Type 1 diabetes. Because both positive and negative effects of GLP-1RAs and SGLT2is were shown in strictly regulated clinical trials, their real-world effects have been unclear.   To examine their efficacy, Dr. Lingvay, along with colleagues Khary Edwards, M.D., a former Endocrinology fellow at UTSW, and Xilong Li, M.B.A., Senior Database Analyst at UTSW, searched medical records for Type 1 diabetes patients treated at UT Southwestern who used any GLP-1RAs and/or SGLT2is for at least 90 days before Oct. 31, 2021. Their search turned up 104 patients: 65 who had used GLP-1RAs exclusively, 28 who had used SGLT2is exclusively, and 11 who had used both either concurrently or sequentially.   After a year of use, patients on GLP-1RAs had significant reductions in weight, glycated hemoglobin A1C (a three-month average measure of blood sugar), and total daily dose of insulin. SGLT2i users had significant reductions in hemoglobin A1C and basal insulin, a baseline dose delivered outside of meals.   However, SGLT2i users were about three times more likely than GLP-1RA users to experience DKA. Just over a quarter of patients taking either class of drugs stopped due to side effects such as gastrointestinal problems.   The study authors say these results suggest both types of drugs can be beneficial to patients with Type 1 diabetes, but close monitoring is required. Specifically when using SGLT2is, extreme caution is advised in selecting patients with the lowest risk of DKA, performing detailed education about the risk of DKA, and ensuring careful monitoring to prevent its occurrence.   https://www.utsouthwestern.edu/newsroom/articles/year-2023/february-type-1-diabetes.html XX XX   XX Athletic Greens XX COVID-19 patients who took the diabetes drug metformin for two weeks after a diagnosis were less likely to develop long COVID-19 symptoms, according to results from a clinical trial.   The trial enrolled about a thousand participants who were symptomatic with a COVID-19 infection for less than a week. Participants were randomly selected to receive a placebo or one of three drugs: metformin, ivermectin or fluvoxamine. About 6 percent of people who took metformin later developed long COVID-19, as determined by a medical diagnosis. In the placebo group, 10.6 percent of participants developed long COVID-19.   This meant that overall people who took metformin were 42 percent less likely to develop long COVID-19 compared to people who got the placebo.   The authors also note that the beneficial effect is potentially stronger for people who started taking metformin less than four days from symptom onset compared to people who started the medication four or more days after their first symptoms. The participants who received the two other drugs, ivermectin and fluvoxamine, did not see any benefits in terms of preventing long COVID-19. https://thehill.com/policy/healthcare/3889797-diabetes-drug-proves-beneficial-in-preventing-long-covid-in-clinical-trials/ XX Great article.. https://www.nytimes.com/2023/03/03/sports/baseball/garrett-mitchell-brewers.html XX On the podcast next week.. Ginger Vieira, author and diabetes advocate. Our last episode was with a family whose son was treated with Tzield to delay his T1D diagnosis. That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.  

President Biden recently signed into law the FDA Modernization Act 2.0, new legislation that ends the FDA's mandate that all drugs be tested on animals prior to human clinical trials. The new law doesn't prohibit animal testing, but it does give companies the choice of whether to conduct animal experiments or not, and could lead to many fewer animals being used as test subjects.  If we don't use animals as test tubes prior to human clinical trials, what should we use? Emulate claims it has the answer. The organ-on-a-chip company's CEO Jim Corbett testified before Congress in favor of the new legislation and says his company's products deliver much more reliable data than does animal experimentation.  And why shouldn't it? We all know that rats (the most popular animal on whom to experiment) have pretty different biologies than humans. For example, people with pet rats are regularly warned not to give their rats onions since it can sicken them. We all know dogs are apparently not supposed to eat chocolate. Yet humans do just fine eating these foods that are toxic to rats and dogs.  So what if we could test on actual human cells that have been placed on chips which mimic the functions of a human body? In this episode, Jim discusses Emulate's technology, its promise to slash the number of animals used for testing while delivering safe drugs to market more quickly, who opposes their efforts, and where this is all leading us.  Emulate so far has raised a whopping quarter-billion dollars of venture capital investment, so someone believes that these folks are onto something big. Time will tell, and for now, their CEO will tell you the Emulate story. Discussed in this episode Emulate was birthed from Don Ingber's lab at Harvard with funding from DARPA Fast Company and WIRED on Emulate's work. Nature Communications Medicine Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) Science Translational Medicine Reproducing human and cross-species drug toxicities using a Liver-Chip (2019) Jim recommends the book Endurance to would-be startup founders Jim credits the Center for a Humane Economy with leading the passage of the FDA Modernization Act 2.0. More about Jim Corbett Jim Corbett has served as a leader of successful international businesses across diverse sectors, including biotechnology, medical imaging, analytical instruments and in vitro diagnostics. His experience ranges from Fortune 100 companies to entrepreneurial start-ups.  Until becoming the CEO of Emulate, he served in leadership roles at PerkinElmer during an 11-year tenure, including Executive Vice President and President of Discovery & Analytical Solutions. His other roles at PerkinElmer included President of Diagnostics & Life Sciences, Senior Vice President of Life Sciences Solutions, and Vice President of North America Genetic Screening. Prior to PerkinElmer, Corbett was President of ViaCell, Inc. which was acquired by PerkinElmer in 2007. Previously, he co-founded CADx Systems, a company focused on the oncology market, where he held the position of Executive Vice President and Director with responsibility for worldwide sales and marketing, technical support and business development. Following the 2004 acquisition of CADx by iCAD, Inc., he was named Chief Commercial Officer.  In addition, Corbett worked for Abbott Laboratories for 14 years in a variety of sales and marketing positions including Worldwide Marketing Manager for Abbott Diagnostics Immunoassay Systems and Region Manager for Abbott Diagnostics. Corbett holds a Bachelor of Science from The University of Massachusetts, Amherst.

Monday, January 23rd, 2023 Today, in the Hot Notes: Judge Middlebrooks awards Hillary et al nearly one million dollars in sanctions for Trump and Habba's vexatious lawsuit; a 1/6 defendant pleads guilty to death threats against AOC; former White House aide and current douchebag Johnny McEntee has testified before Jack Smith's Grand Jury; the DoJ shuts down Jim Jordan's dumb subcommittee investigating the investigation; three active-duty Marines have been charged for their participation in the insurrection, Abbott Laboratories is now under federal criminal investigation for the baby formula crisis; a new film about Kavanaugh premieres at Sundance, 10 are dead in a mass shooting in Monterrey Park, California amid Chinese New Year celebrations; Jeff Zients is set to replace Ron Klain as the White House Chief of Staff; plus Allison delivers your Good News. Check out other MSW Media podcasts https://mswmedia.com/shows/ Follow AG and Dana on Twitter: Dr. Allison Gill  https://twitter.com/allisongill https://twitter.com/MuellerSheWrote https://twitter.com/dailybeanspod Dana Goldberg https://twitter.com/DGComedy Minocqua Brewing - Wisconsin. Help fight the Gerrymander https://secure.actblue.com/donate/minocqua-brewing-co-superpac?fbclid=IwAR23Yd_oJLHNNR7YwCgP70DwfV0IiCTKnoad95xvWz98A71427fRkY24Ltw Have some good news, a confession, a correction? https://www.dailybeanspod.com/confessional/ Listener Survey: http://survey.podtrac.com/start-survey.aspx?pubid=BffJOlI7qQcF&ver=short Promo Code: Thanks to ZBiotics. Get 15% off at ZBiotics.com/dailybeans and use the code DAILYBEANS Follow the Podcast on Apple: https://apple.co/3XNx7ck Want to support the show and get it ad-free and early? https://dailybeans.supercast.tech Or https://patreon.com/thedailybeans Or subscribe on Apple Podcasts https://apple.co/3UKzKt0 Learn more about your ad choices. Visit megaphone.fm/adchoices

The MR Crew are back from the long weekend! Sam and Emma host David Enrich, business investigations editor at the New York Times, to discuss his recent book Servants of the Damned: Giant Law Firms, Donald Trump, and the Corruption of Justice. First, Sam and Emma run through updates on the GOP and the debt ceiling, the death toll from Russia's action in Dnipro, the arrest of a losing GOP candidate in New Mexico, and Israeli protests of Netanyahu's abuse of the judicial branch, before parsing through why complete different actions by Biden and Trump (involving classified documents) have resulted in different responses from US political institutions. Then, David Enrich joins as he begins to walk through the story of the entrance of lawyers and law firms into the world of advertising in 1977, and how it created the world of financialized, amoral, corporate global law firms that we see today. Stepping back, Enrich then looks to the evolution of the Jones Day law firm as a model of the greater industry, first diving into their work in the 1940s representing a natural gas company in the wake of an explosion in Milwaukee and their emphasis on maintaining integrity and bolstering community trust, rather than fighting tooth and nail to against any reparation as a company would today, before contrasting this with their recent work intimidating and threatening local governments with lawsuits over attempts to ban the sale of flavored tobacco products. Next, David, Emma, and Sam walk through the main justifications for such horrific actions on behalf of corporate behemoths, as these firms hide behind the Constitution's guarantee of representation for people accused of crimes and shirk claims of greed with pro-bono work, exploring the obvious immorality behind these lawyers' amoral facade, before taking on two more examples of this growing trend of law firms falling in line with corporate greed, the Texas Two-Step, and Abbott Laboratories' baby formula disaster. Wrapping up the interview, David walks through the reform he would most like to see, with an emphasis on the ABA, mainstream media's coverage of law firms, and the exploitative cycle of legal education. And in the Fun Half: Sam and Emma discuss poverty as a policy choice, Tucker suggests more congresspeople smoke crack on the House floor, and Marc Silvestry of Revere City Council absolutely shuts down some bonkers anti-homeless arguments on the floor. They also cover Sarah Huckabee Sanders' efficient first few works in office, Jeremy from LA discusses the coverage of psychedelics online, and Nathan from Alabama dives into the Warrior Met Coal strike and comparisons with Glacier North West's teamsters' action. Casey from Tennessee has an extended discussion on the South's relationship to labor and culture wars, and walks through his own evolution from Trumper to Sederista, plus, your calls and IMs! Check out David's book here: https://www.harpercollins.com/products/servants-of-the-damned-david-enrich?variant=40153396346914 Become a member at JoinTheMajorityReport.com: https://fans.fm/majority/join Buy tickets to the Left Reckoning/This Is Revolution live show here!: https://www.eventbrite.com/e/this-is-revolution-left-reckoning-tickets-476781264597 Subscribe to the ESVN YouTube channel here: https://www.youtube.com/esvnshow Subscribe to the AMQuickie newsletter here: https://am-quickie.ghost.io/ Join the Majority Report Discord! http://majoritydiscord.com/ Get all your MR merch at our store: https://shop.majorityreportradio.com/ Get the free Majority Report App!: http://majority.fm/app Check out today's sponsors: Aura: Go to my sponsor https://aura.com/majority to try 14 days free and let Aura go to work protecting your private information online HoldOn Bags: To shop plant based bags and replace single use plastics all over your home, visit https://holdonbags.com/MAJORITY or enter MAJORITY at checkout to save 20% off your order. Henson Shaving: Go to https://hensonshaving.com/majority and use code MAJORITY for a free 100-pack of blades! Follow the Majority Report crew on Twitter: @SamSeder @EmmaVigeland @MattBinder @MattLech @BF1nn @BradKAlsop Check out Matt's show, Left Reckoning, on Youtube, and subscribe on Patreon! https://www.patreon.com/leftreckoning Subscribe to Discourse Blog, a newsletter and website for progressive essays and related fun partly run by AM Quickie writer Jack Crosbie. https://discourseblog.com/ Check out Ava Raiza's music here! https://avaraiza.bandcamp.com/ The Majority Report with Sam Seder - https://majorityreportradio.com/